<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-5251-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BATIPAN 100 mg per 50 ml - VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OXALIPLATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        237.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Actavis Italy SpA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Actavis Italy SpA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XA03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Batipan is used to treat metastatic (advanced) cancer of the colon (large bowel) or rectum (back passage), or as additional treatment following surgery to remove a tumour (growth) in the colon.<br />It is used in combination with other anticancer agents, 5-fluorouracil (5-FU) and folinic acid (FS).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Batipan</p><p>- if you are allergic to oxaliplatin or any of the other ingredients of this medicine (listed in section 6). - if you are breast-feeding<br />- if you already have a reduced number of blood cells (white blood cells and/or platelets).<br />- if you already have tingling and numbness in the fingers and/or toes, and have difficulty performing</p><p>delicate tasks, such as buttoning clothes - if you have severe kidney problems</p><p>Even if you are male, please ensure that you read the section of this leaflet that concerns pregnancy and breast-feeding.</p><p>Take Special care with Oxaliplatin PowderTalk to your doctor or pharmacist before receiving Batipan&nbsp;1</p><p><img alt="page1image16743424" width="258.840000" height="0.360000" src="blob:https://sdi.sfda.gov.sa/2dea1a5b-ab7b-481f-801c-5f8ebdf5b04c" /></p><ul><li><p>- &nbsp;if you have ever suffered an allergic reaction to platinum-containing medicines such as carboplatin or cisplatin. Allergic reactions can occur during any oxaliplatin infusion.</p></li><li><p>- &nbsp;if you have moderate kidney problems</p></li><li><p>- &nbsp;if you have any liver problems</p></li><li><p>- &nbsp;if you are pregnant or planning a pregnancy. It is very important that you discuss this with your doctor</p><p>before you receive any treatment.</p></li><li><p>- &nbsp;if your blood cell counts are too low after previous oxaliplatin treatment. Your doctor will perform tests</p><p>to check that you have sufficient blood cells before treatment.</p></li><li><p>- &nbsp;if you have symptoms of nerve damage such as weakness, numbness, disturbances of feeling or taste</p><p>after previous oxaliplatin treatment. These effects are often triggered by exposure to cold. If you notice such symptoms tell your doctor, especially if they are troublesome and/or last longer than 7 days. Your doctor will carry out neurological examinations, before and regularly during treatment, especially if you are given other drugs which may cause nerve damage. Symptoms of nerve damage can persist after the end of the treatment.</p></li><li><p>- &nbsp;if you also receive 5-fluorouracil, because the risk of diarrhoea, vomiting, sore mouth and blood abnormalities is increased.</p></li><li><p>- &nbsp;if you experience symptoms such as headache, altered mental functioning, seizures and abnormal vision from blurriness to vision loss (symptoms of reversible posterior leukoencephalopathy syndrome, a rare neurological disorder).</p><p>Other medicines and Batipan</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Pregnancy, breast-feeding and fertility</p><p>Batipan should not be used during pregnancy. It is therefore important to tell your doctor if you are pregnant. If you become pregnant during your treatment, you must inform your doctor immediately.</p><p>Effective birth control to prevent pregnancy is advised during treatment and after the end of treatment for the following 4 months for women and for 6 months for men.</p><p>Oxaliplatin may have an anti-fertility effect which could be irreversible. Men treated with oxaliplatin are therefore advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment.</p><p>Breast-feeding should be discontinued before starting treatment with Batipan.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>It is unknown whether treatment with Batipan affects the ability to drive and use machines.<br />If you feel sleepy and/or dizzy or have nausea or vomiting, following oxaliplatin infusion do not drive, operate potentially dangerous machinery, or engage in other activities that may be hazardous because of decreased alertness.</p><p>Oxaliplatin treatment may transiently affect vision. If you have problems with vision, do not drive, operate potentially dangerous machinery, or engage in other activities that may be hazardous.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>For adults only.<br />Batipan will be prescribed for you by a specialist in cancer treatment.<br />Batipan is given by injection into a vein (an intravenous infusion) over a 2 to 6 hour period.<br />The dose of Batipan is based on your body surface area (calculated from your height and weight). The dose will also depend on results of blood tests and whether you have previously experienced side effects with Batipan. The usual dose for adults including the elderly is 85 mg/m2&nbsp;of body surface area once every 2 weeks at the same time as folinic acid and before the infusion of 5-fluorouracil. The duration of the treatment will be determined by your doctor. Your treatment will last a maximum of 6 months when used after complete resection of your tumour.</p><p>2</p><p>The needle must remain in the vein while the drug is being given. If the needle comes out or becomes loose, or the solution is going into the tissue outside the vein (you may feel discomfort or pain) -&nbsp;tell the doctor or nurse immediately.</p><p>If you use more Batipan than you should</p><p>As this medicine is given in a hospital, it is unlikely that you will be given too little or too much. However tell your doctor if you have any concerns.</p><p>If you forget to use Batipan</p><p>Oxaliplatin needs to be given on a fixed schedule. Be sure to keep all appointments. If you miss a dose, you should discuss this with your doctor. Your doctor will decide when you should be given your next dose of Oxaliplatin.</p><p>If you stop treatment with Batipan</p><p>Stopping your treatment with Oxaliplatin may stop the effect on tumour growth. Do not stop treatment with Oxaliplatin unless you have discussed this with your doctor.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any side effect it is important that you inform your doctor before your next treatment.</p><p>Immediately inform you doctor if you notice any of the following:</p><p>- Abnormal bruising, bleeding or signs of infection such as a sore throat and high temperature. - Persistent or severe diarrhoea or vomiting.<br />- Presence of blood or dark brown coffee-coloured particles in your vomit<br />- Sore lips or mouth ulcers (stomatitis/mucositis).</p><p>- Unexplained symptoms from the respiratory system such as non-productive cough, breathing difficulties or voice alterations.</p><p>- Symptoms of an allergic reaction such as swelling of hands, feet, ankles, face, lips, mouth or throat (which may cause difficulties in swallowing or breathing).</p><p>- A group of symptoms such as headache, altered mental functioning, seizures and abnormal vision from blurriness to vision loss (symptoms of reversible posterior leukoencephalopathy syndrome, a rare neurological disorder).</p><p>Very common side effects (may affect more than 1 in 10 peopole):</p><ul><li><p>- &nbsp;Effects on the nerves (peripheral sensory neuropathy). You may feel a tingling and/or numbness in the fingers, toes, around the mouth or in the throat which may sometimes occur in association with cramps. This side effect is often triggered by exposure to cold e.g. opening a refrigerator or holding a cold drink. You may also have difficulty in performing delicate tasks, such as buttoning clothes. Although in the majority of cases these symptoms disappear completely there is a possibility of continued symptoms of peripheral sensory neuropathy (weakness or numbness because of nerve damage) after the end of the treatment.</p></li><li><p>- &nbsp;Some people have experienced a tingling shock-like sensation passing down the arms or trunk when the neck is flexed.</p></li><li><p>- &nbsp;Oxaliplatin can sometimes cause an unpleasant sensation in the throat, in particular when swallowing, and give the sensation of shortness of breath. This sensation, if it happens, usually occurs during or within hours of the infusion and may be triggered by exposure to the cold. Although unpleasant, it will not last long and goes away without the need for any treatment. Your doctor may decide to alter your treatment as a result.</p></li><li><p>- &nbsp;Signs of infection such as a sore throat and high temperature.</p></li><li><p>- &nbsp;Decreased number of white blood cells, which increase the risk of infection.</p></li><li><p>- &nbsp;Decreased number of blood platelets, which increase the risk of bleedings and bruising.</p></li></ul><p>3</p><ul><li><p>- &nbsp;Decreased number of red blood cells, which may make the skin pale, and cause weakness or breathlessness. Your doctor will take blood to check that you have sufficient blood cells before you start treatment and before each subsequent course.</p></li><li><p>- &nbsp;Allergic reaction&nbsp;&ndash;&nbsp;skin rash including red itchy skin, swelling of hands, feet, ankles, face, lips, mouth or throat (which may cause difficulties in swallowing or breathing) and can make you feel like fainting.</p></li><li><p>- &nbsp;Loss or lack of appetite.</p></li><li><p>- &nbsp;High levels of glucose (blood sugar) in your blood, which may cause thirst, dry mouth and frequent</p><p>urination.</p></li><li><p>- &nbsp;Low levels of potassium in your blood, which may cause abnormal heart beat.</p></li><li><p>- &nbsp;Low levels of sodium in your blood, which may cause fatigue and confusion, muscular jerking, cramps or</p><p>coma.</p></li><li><p>- &nbsp;High levels of sodium in your blood, which may cause weakness or swelling caused by fluid retention.</p></li><li><p>- &nbsp;Taste alterations.</p></li><li><p>- &nbsp;Headache.</p></li><li><p>- &nbsp;Nose bleeds.</p></li><li><p>- &nbsp;Breathlessness.</p></li><li><p>- &nbsp;Cough.</p></li><li><p>- &nbsp;Nausea (feeling sick) and vomiting (being sick) - medication to prevent the sickness is usually given</p><p>before treatment and may be continued after treatment.</p></li><li><p>- &nbsp;Diarrhoea, if you suffer from persistent or severe diarrhoea or vomiting contact your doctor immediately</p><p>for advice.</p></li><li><p>- &nbsp;Sore lips or mouth ulcers.</p></li><li><p>- &nbsp;Abdominal pain, constipation.</p></li><li><p>- &nbsp;Skin disorder.</p></li><li><p>- &nbsp;Hair loss.</p></li><li><p>- &nbsp;Back pain.</p></li><li><p>- &nbsp;Fatigue, weakness and pain.</p></li><li><p>- &nbsp;Reaction close to or at the injection site during the infusion (local pain, redness, swelling of skin,</p><p>hardening of skin, death of skin tissue).</p></li><li><p>- &nbsp;Fever.</p></li><li><p>- &nbsp;Alteration in blood tests including those relating to abnormalities in liver function.</p></li><li><p>- &nbsp;Weight increase.</p></li><li><p>- &nbsp;Rigors (tremors).</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>- Runny nose (rhinitis).<br />- Upper respiratory tract infection.<br />- Dehydration.<br />- Depression, sleeplessness.<br />- Dizziness.<br />- Swelling of the nerves to the muscles.<br />- Rigidity, intolerance of bright light andheadache (meningism).<br />- Inflammation of the conjunctiva, abnormal vision.<br />- Abnormal bleeding, blood in the urine/stools.<br />- Blood clots, usually in the leg, which can cause pain, swelling or redness.<br />- Blood clots in the lungs, which can cause chest pain and breathing difficulties.<br />- Flushing.<br />- Hiccups, chest pain.<br />- Indigestion and heart burn.<br />- Flaking skin, skin rash, increased sweating and nail disorders.<br />- Joint pain and bone pain.<br />- Pain on passing urine and changes in the frequency of urination.<br />- Alteration in blood test which measures the kidney function.<br />- Weight decrease.<br />- Tightness of the chest caused by cramp of the respiratory tract muscles (bronchospasm). - Decrease in blood pressure.</p></li></ul><p>4</p><ul><li><p>- &nbsp;Shock (strong blood pressure drop, paleness, restlessness, rapid heart rate, moist skin, decreased consciousness) caused by a sudden vascular dilatation as a result of a severe hypersensitivity reaction to certain substances (anaphylactic shock).</p></li><li><p>- &nbsp;Swelling of hands, feet, ankles, face, lips, mouth or throat which may cause difficulties in swallowing or breathing (angioedema).</p></li><li><p>- &nbsp;Blood abnormality (deficiency of certain white blood cells) accompanied by increased susceptibility to infections (febrile neutropenia/neutropenic sepsis).</p></li><li><p>- &nbsp;High blood pressure</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>- Hearing problems.<br />- Blockage or swelling of the bowel.<br />- Nervousness.<br />- Blood test which indicates increased acidity in the blood.<br />- Jaw spasms, muscle spasms, involuntary muscle contractions, muscle twitching. - Difficulties with co-ordination, balance, and walking.<br />- Throat or chest tightness.<br />- Eye disorders such as drooping of the upper eye lid, and double vision.<br />- Loss or impairment of the voice, roughness of the voice (hoarseness).<br />- Abnormal tongue sensation, difficulty speaking.<br />- Facial pain and/or eye pain.</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p>- Slurred speech.<br />- Deafness.<br />- Unexplained symptoms from the respiratory system such as non-productive cough, breathing difficulties</p><p>or crackles (interstitial lung disease, pulmonary fibrosis).<br />- Inflammation of the large bowel which may cause abdominal pain or diarrhoea (colitis).<br />- Blood abnormality (lack of platelets) caused by an allergic reaction associated with bruises and abnormal</p><p>bleeding (immunoallergic thrombocytopenia).<br />- Lack of red blood cells caused by too much degradation of blood (haemolytic anaemia).<br />- Transient reduction in visual acuity, disturbance of the visual field, inflammation of the optic nerve</p><p>(optic neuritis).<br />- Inflammation of the pancreas which can cause upper abdominal pain, nausea or vomiting.</p><p>Very rare side effects (may affect up to 1 in 10,000 people):</p><p>- Liver disease<br />- Kidney inflammation and kidney failure</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC) +966-11-2038222. Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000. E-mail: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />This medicinal product does not require any special storage conditions when the vial is unbroken. Do not use Batipan after the expiry date which is stated on the carton and label.<br />The expiry date refers to the last day of that month.</p><p>The reconstituted solution should immediately be diluted with 5% glucose soltuion to give a concentration between 0.2mg/ml and 0.7mg/ml. Once diluted the infusion solution should be used immediately. Chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C</p><p>Oxaliplatin should not come into contact with the eyes or skin. If there is any accidental spillage, tell the doctor or nurse immediately.</p><p>When the infusion has finished, any remaining Batipan will be disposed of carefully by the doctor or nurse. This medicine is for single use only; any unused solution must be disposed of in accordance with local requirement.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li><p>- &nbsp;The active substance is oxaliplatin.</p></li><li><p>- &nbsp;The other ingredient is lactose monohydrate.</p><p>One ml of the reconstituted concentrate solution contains 5 mg oxaliplatin.<br />50 mg vial: Each vial contains 50 mg oxaliplatin for reconstitution in 10 ml of solvent. 100 mg vial: Each vial contains 100 mg oxaliplatin for reconstitution in 20 ml of solvent.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Powder for solution for infusion: A white or almost white powder, which is provided in a colourless glass vial that has a rubber closure and has a metallic cap containing a plastic disk.
Vial will be packed with or without a protective plastic overwrap.
Pack sizes:
1 x 50 mg vial 1 x 100 mg vial

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ol><li><p>Tadaw&nbsp;iomedical company Olaya st, Riyadh,<br />Saudi Arabia</p><p>Manufacturer</p><p>Actavis&nbsp;</p><p>&nbsp;</p><p>S.C. Sinda&nbsp;S.R.L. 11 Ion Mihalache Blvd 011171 Bucharest Romania</p></li></ol>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم&nbsp;<strong>باتيبان</strong>&nbsp;لمعالجة السرطان المتنقل (المُتقدم) سرطان القولون (الأمعاء الغليظة) أو المُستقيم&nbsp;&nbsp;(الشرج), أو كمعالجة إضافية عقب عملية جراحية لإزالة ورم ما (نُمو) في القولون.</p><p dir="RTL">ويُستخدم بالمشاركة مع مواد أخرى مضادة للسرطان، 5- فلوروراسيل (&nbsp;(5-FUوحمض الفولونيك&nbsp;(FA).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا&nbsp;</strong><strong>تستخدم</strong><strong>&nbsp;باتيبان</strong></p><p dir="RTL">- إذا كنت تتحسس من أوكساليبلاتين أو من أية مكونات أخرى لهذا الدواء (المدرجة في البند 6).</p><p dir="RTL">- إذا كنتِ مرضعة</p><p dir="RTL">- إذا كان لديك أصلاً انخفاض في تعداد خلايا الدم (خلايا الدم البيضاء و/أو الصفيحات).</p><p dir="RTL">- إذا كان لديك أصلاً تنميل وخَدَر في أصابع اليدين و/أو أصابع القدمين, وتعاني من صعوبة في أداء مهام خفيفة, مثل تزرير الملابس</p><p dir="RTL">- إذا كان لديك مشاكل كلوية شديدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حتى وإن كنت ذَكَراً, رجاء التأكد من أنك قرأت القسم الخاص في هذه النشرة الذي يهتم بالحمل والرضاعة.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>توخَّى العناية الخاصة مع مسحوق أوكساليبلاتين</strong></p><p dir="RTL"><u>تحدث إلى طبيبك أو الصيدلي قبل تلقي باتيبان</u></p><p dir="RTL">- إذا كنت قد عانيت من رد فعل تحسسي لأدوية حاوية على بلاتينوم مثل كاربوبلاتين أو سيسبلاتين. ذلك لأن ردود الفعل التحسسية قد تحدث أثناء أي تسريب من دواء أوكساليبلاتين.</p><p dir="RTL">- إذا كان لديك مشاكل&nbsp;&nbsp;كلوية بسيطة</p><p dir="RTL">- إذا كان لديك أية مشاكل في الكبد</p><p dir="RTL">- إذا كنتِ حاملاً أو عازمةً على الحمل. من المهم جداً أن تبحثي ذلك مع طبيبكِ قبل أن تتلقي أية معالجة.</p><p dir="RTL">- إذا كان تعداد خلايا الدم لديك منخفض جداً بعد معالجة سابقة بدواء أوكساليبلاتين. سوف يجري طبيبك فحوصاً للتحقق من أن لديك خلايا دم كافية قبل المعالجة.&nbsp;</p><p dir="RTL">- إذا كان لديك أعراض تلف أعصاب مثل الضعف, الخدر, إضطرابات بالشعور أو التذوق بعد معالجة سابقة بدواء أوكساليبلاتين. هذه التأثيرات يُحركها غالباً التعرض للبرد. إذا لاحظت مثل هذه الأعراض أخبر طبيبك, خاصة إذا كانت مزعجة و/أو تدوم أكثر من 7 أيام. وإن طبيبك سوف يجري فحوصاً عصبية, قبل وبشكل دوري أثناء المعالجة, خاصة إذا أُعطيت لك أدوية أخرى من شأنها أن تسبب تلفاً بالأعصاب. يمكن أن تدوم أعراض تلف الأعصاب بعد انتهاء المعالجة.</p><p dir="RTL">- إذا تلقيت أيضاً 5- فلوروراسيل, بسبب خطورة الإسهال, الإقياء, التهاب الفم وازدياد الحالات غير الطبيعية في الدم.</p><p dir="RTL">- إذا واجهت أعراض مثل وجع الرأس, تغير بالوظائف العقلية, نوبات ورؤية غير طبيعية من تشوش الرؤية إلى فقدان الرؤية (أعراض متلازمة إعتلال المادة البيضاء في الجانب الخلفي الإنعكاسي للدماغ, واضطراب نادر في الأعصاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وباتيبان</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول, أو تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">يجب عدم استخدام&nbsp;<strong>باتيبان</strong>&nbsp;أثناء الحمل. لذلك من المهم أن تخبري طبيبكِ إذا كنتِ حاملاً. إذا أصبحت حاملاً أثناء المعالجة, عليكِ أن تخبري طبيبكِ فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُنصح بتَحَكُّمٍ فعّال بالولادَة لمنع حدوث الحمل أثناء المعالجة وبعد الانتهاء منها لمدة 4 أشهر للنساء ولمدة 6 أشهر للرجال.&nbsp;</p><p dir="RTL">يمكن أن يكون لدواء أوكساليبلاتين تأثير مضاد للخصوبة والذي قد يكون غير انعكاسي. لذلك يُنصح الرجال الذين يعالجون بدواء أوكساليبلاتين أن لا يسعوا وراء إنجاب طفلٍ أثناء المعالجة وحتى مدة 6 أشهر بعد المعالجة والتماس المشورة&nbsp;&nbsp;بشأن حفظ الحيوانات المنوية قبل المعالجة.</p><p dir="RTL">يجب التوقف عن الرضاعة الطبيعية قبل البدء بالمعالجة بدواء&nbsp;<strong>باتيبان</strong>.</p><p dir="RTL">التمس مشورة الطبيب أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">من غير المعروف ما إذا كانت المعالجة بدواء&nbsp;<strong>باتيبان</strong>&nbsp;تؤثر على قدرة القيادة أو استخدام الآلات.</p><p dir="RTL">إذا شعرت بنعاس و/أو دوخة أو&nbsp;أصبت بغثيان أو إقياء, عقب تسريب أوكساليبلاتين فلا تقود السيارة, ولا تشغل الآلات المحتمل أن تكون خطيرة, ولا تُشارك بأنشطة أخرى يمكن أن تكون خطيرة بسبب تناقص الإنتباه.</p><p dir="RTL">يمكن أن تؤثر المعالجة بدواء أوكساليبلاتين على الرؤية بشكل عابر. فإذا كان لديك مشاكل بالرؤية, فلا تقود السيارة, ولا تشغل الآلات المحتمل أن تكون خطيرة, ولا تُشارك بأنشطة أخرى يمكن أن تكون خطيرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3 &ndash; كيف تستخدم باتيبان</strong></p><p dir="RTL">للبالغين فقط.</p><p dir="RTL">سيوصف&nbsp;<strong>باتيبان</strong>&nbsp;لك من قبل مختص بمعالجة السرطان.</p><p dir="RTL">يُعطى&nbsp;<strong>باتيبان</strong>&nbsp;حقناً بالوريد (تسريب وريدي) على فترة 2 إلى 6 ساعات.</p><p dir="RTL">تستند جرعة&nbsp;<strong>باتيبان</strong>&nbsp;على مساحة سطح جسمك (وتُحتسب من طولك ووزنك). وتعتمد الجرعة أيضاً على نتائج فحوص الدم وعلى ما إذا كنت قد عانيت سابقاً من تأثيرات جانبية من&nbsp;<strong>باتيبان</strong>. الجرعة الاعتيادية للبالغين بما فيهم المُسنين هي 85 ملغ/متر<sup>2</sup>&nbsp;من مساحة سطح الجسم مرة واحدة كل أسبوعين بنفس الوقت مثل حمض فولينيك وقبل حقن 5- فلوروراسيل. وسيحدد طبيبك مدة المعالجة. ستدوم معالجتك مدة أقصاها 6 أشهر عند استخدامه بعد الاستئصال الكامل لورمك.</p><p dir="RTL">يجب أن تبقى الإبرة بالوريد أثناء إعطاء الدواء. إذا خرجت الإبرة أو تخلخلت, أو إذا دخل المحلول في النسيج خارج الوريد (قد تشعر بالانزعاج أو الألم) -&nbsp;<strong>أخبر طبيبك أو الممرضة فوراً.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت أكثر مما ينبغي من باتيبان</strong></p><p dir="RTL">طالما أن هذا الدواء يُعطى في المشفى, فمن غير المحتمل أن يُعطى لك كمية قليلة جداً أو كثيرة جداً. ومع ذلك أخبر طبيبك إذا كانت لديك أية مخاوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تستخدم باتيبان</strong></p><p dir="RTL">يحتاج أوكساليبلاتين أن يُعطى بمواعيد ثابتة. تأكد من الالتزام بكل المواعيد. إذا نسيت جرعة, يجب أن تبحث ذلك مع طبيبك. وسوف يقرر طبيبك متى ينبغي أن تُعطى جرعتك التالية من أوكساليبلاتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أوقفت المعالجة بدواء باتيبان</strong></p><p dir="RTL">إن إيقاف معالجتك بدواء أوكساليبلاتين قد يوقف التأثير على نمو السرطان. فلا توقف المعالجة بدواء أوكساليبلاتين ما لم تبحث ذلك مع طبيبك.</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا المستحضر, اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية الأخرى, يمكن أن يُسبب تأثيرات جانبية, وإن كانت لا تحدث لكل شخص. فإذا واجهت أية تأثيرات جانبية من المهم أن تخبر طبيبك قبل المعالجة التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>أخبر طبيبك فوراً إذا لاحظت أيّاً ممّا يلي:</em></strong></p><p dir="RTL">- كدمة غير طبيعية, نزيفاً أو علامات عن إصابة مثل التهاب الحلق وارتفاع الحرارة.</p><p dir="RTL">- إسهال مستمر أو شديد أو إقياء.</p><p dir="RTL">- وجود دم أو ذرات بنية غامقة بلون القهوة في إقيائك.</p><p dir="RTL">- شفتين ملتهبتين أو تقرحات بالفم (التهاب الفم&nbsp;/&nbsp;التهاب الأغشية المخاطية).</p><p dir="RTL">- أعراض غير مفسرة من جهاز التنفس مثل سعال غير مُنتج, صعوبات بالتنفس أو تغيرات بالصوت.</p><p dir="RTL">- أعراض رد فعل تحسسي مثل تورُّم اليدين, القدمين, الكاحلين, الوجه, الشفتين, الفم أو الحلق (والتي يمكن أن تسبب صعوبات في البلع أو التنفس).</p><p dir="RTL">- مجموعة أعراض مثل وجع الرأس, تغير الوظائف العقلية, نوبات ورؤية غير طبيعية من التشويش إلى فقدان الرؤية (أعراض متلازمة اعتلال المادة البيضاء في الجانب الخلفي الإنعكاسي للدماغ, واضطراب عصبي نادر).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تأثيرات جانبية شائعة جدا (يمكن أن تؤثر بأكثر من 1 من كل 10 أشخاص):</em></strong></p><p dir="RTL">- تأثيرات على الأعصاب (اعتلال عصبي حسي محيطي). قد تشعر بتنميل و/أو خَدَر في أصابع اليدين, أصابع القدمين, حول الفم أو في الحلق والتي يمكن أن تحدث أحياناً بالمشاركة مع تشنجات. هذا التأثير الجانبي غالباً ما يحركه التعرض للبرد مثل فتح البراد أو مسك شراب بارد. وقد يحدث لك أيضاً صعوبة في أداء مهام خفيفة, مثل تزرير الملابس. مع أن في غالبية هذه الحالات تزول هذه الأعراض تماماً فهناك احتمال استمرارية أعراض الاعتلال العصبي الحسي (ضعف أو خَدَر بسبب تلف عصبي) بعد الانتهاء من المعالجة.</p><p dir="RTL">- لقد واجه بعض الأشخاص إحساس صدمة شبيهة بالتنميل تسري في الذراعين أو الجذع عند ثني الرقبة.</p><p dir="RTL">- يمكن أن يسبب أوكساليبلاتين أحياناً إحساساً مزعجاً في الحلق, وبخاصة عند البلع, ويُعطي إحساساً بضيق التنفس. إذا حدث هذا الإحساس، فهو يحدث عادة أثناء أو خلال ساعات الحقن ويمكن أن يتحرك بالتعرض للبرد. ومع أنه مزعج, فإنه لا يدوم طويلاً ويزول دونما حاجة لأية معالجة. يمكن لطبيبك أن يقرر تغيير معالجتك نتيجة لذلك.</p><p dir="RTL">- علامات الإصابة مثل التهاب الحلق وارتفاع الحرارة.</p><p dir="RTL">- تناقص عدد خلايا الدم البيضاء, مما يزيد خطورة الإصابة.</p><p dir="RTL">- تناقص عدد صفيحات الدم, مما يزيد خطورة النزف والكدمات.</p><p dir="RTL">- تناقص عدد خلايا الدم الحمراء, مما يجعل الجلد شاحباً, ويسبب ضعفاً أو عدم تنفس. وسوف يأخذ طبيبك دماً للتحقق من أن خلايا دمك كافية قبل أن تبدأ معالجتك وقبل كل دورة لاحقة.</p><p dir="RTL">- رد فعل تحسسي, طفح جلدي بما في ذلك جلد حاكّ أحمر, تورُّم اليدين, القدمين, الكاحلين, الوجه, الشفتين, الفم أو الحلق (مما يسبب صعوبات في البلع أو التنفس) ويمكن أن يجعلك تشعر بالإغماء.</p><p dir="RTL">- فقدان أو نقص الشهية.</p><p dir="RTL">- مستويات مرتفعة من الغلوكوز (سكر الدم) في دمك, مما يسبب العطش, جفاف الفم وزيادة في مرات التبول.</p><p dir="RTL">- مستويات منخفضة من البوتاسيوم في دمك, مما يسبب ضربات قلب غير طبيعية.</p><p dir="RTL">- مستويات منخفضة من الصوديوم في دمك, مما يسبب تعباً وارتباكاً, وارتجاجاً عضلياً, وتشنجات أو غيبوبة.</p><p dir="RTL">- مستويات عالية من الصوديوم في دمك, مما يسبب ضعفاً أو تورماً ناجماً عن احتباس السوائل.</p><p dir="RTL">- تغيرات في التذوق.</p><p dir="RTL">- وجع رأس.</p><p dir="RTL">- نزيف أنفي.</p><p dir="RTL">- انعدام التنفس.</p><p dir="RTL">- سعال.</p><p dir="RTL">- غثيان (إحساس بالمرض) واقياء (كونك مريض) - يعطى عادة دواء لمنع حدوث المرض قبل المعالجة ويمكن أن يستمر بعد المعالجة.</p><p dir="RTL">- إسهال، إذا كنت تعاني من إسهال مستمر أو شديد أو اقياء, اتصل بطبيبك فوراً للمشورة.&nbsp;<br />- شفتان ملتهبتان أو تقرحات في الفم.</p><p dir="RTL">- وجع بطن, إمساك.</p><p dir="RTL">- اضطراب في الجلد.</p><p dir="RTL">- سقوط الشعر.</p><p dir="RTL">- ألم ظهر.</p><p dir="RTL">- تعب, ضعف وألم.</p><p dir="RTL">- رد فعل قريب من أو في موضع الحقن أثناء التسريب (ألم موضعي, احمرار, تورُّم الجلد, قساوة الجلد, وموت النسيج الجلدي).</p><p dir="RTL">- حمى.</p><p dir="RTL">- تغير في فحوصات الدم بما في ذلك تلك الفحوص المتعلقة بحالات غير طبيعية في وظيفة الكبد.</p><p dir="RTL">- زيادة الوزن.</p><p dir="RTL">- قساوات (ارتعاشات).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>تأثيرات جانبية شائعة ( يمكن أن تؤثر حتى في 1 من كل 10 أشخاص):</em></strong></p><p dir="RTL">- سيلان أنفي.</p><p dir="RTL">- إصابة بمجرى التنفس العلوي.</p><p dir="RTL">- تجفاف.</p><p dir="RTL">- اكتئاب, نوام.</p><p dir="RTL">- دوخة.</p><p dir="RTL">- تورُّم في الأعصاب حتى العضلات.</p><p dir="RTL">- تصلب, عدم تحمل الضوء الساطع, وجع في الرأس (سحايا).</p><p dir="RTL">- التهاب الملتحمتين, رؤية غير طبيعية.</p><p dir="RTL">- نزف غير طبيعي, دم في البول أو البراز.</p><p dir="RTL">- جلطات دموية، عادة في الساق, يمكن أن تسبب ألماً, وتورماً أو احمراراً.</p><p dir="RTL">- جلطات دموية في الرئتين, يمكن أن تسبب ألم صدر وصعوبات في التنفس.</p><p dir="RTL">- تورُّد.</p><p dir="RTL">- حزقات (فُواق), ألم في الصدر.</p><p dir="RTL">- سوء هضم وحرقة.</p><p dir="RTL">- جلد متقشر, طفح جلدي, زيادة التعرق واضطرابات في الأظافر.</p><p dir="RTL">- ألم في المفاصل وألم في العظم.</p><p dir="RTL">- ألم عند مرور البول وتغيرات في تكرار التبول.</p><p dir="RTL">- تغير في فحص الدم الذي يقيس وظيفة الكلى.</p><p dir="RTL">- تناقص الوزن.</p><p dir="RTL">- ضيق صدر ناجم عن تشنج عضلات مجرى التنفس (تشنج القصبات الهوائية).</p><p dir="RTL">- هبوط في ضغط الدم.</p><p dir="RTL">- صدمة (هبوط حاد في ضغط الدم, شحوب, قلق, تسرع ضربات القلب, رطوبة الجلد, تناقص الوعي) بسبب توسع فجائي بالأوعية الدموية نتيجة لرد فعل شديد عالي الحساسية تجاه بعض المواد (صدمة حساسية).</p><p dir="RTL">- تورُّم اليدين, القدمين, الكاحلين, الوجه, الشفتين, الفم أو الحلق, الذي قد يسبب صعوبات في البلع أو التنفس (وذمة وعائية).</p><p dir="RTL">- شذوذ الدم (نقص بعض خلايا الدم البيضاء) مترافق مع تزايد التعرض للإصابة (عدلات تتعلق بالحمى أو انتان العدلات).</p><p dir="RTL">- ضغط دم مرتفع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تأثيرات جانبية غير شائعة ( يمكن أن تؤثر حتى في 1 من كل 100 شخص):</em></strong></p><p dir="RTL">- مشاكل السمع.</p><p dir="RTL">- إنسداد أو تورُّم في الأمعاء الغليظة.</p><p dir="RTL">- اهتياج عصبي (نرفزة).</p><p dir="RTL">- فحص دم يبين حموضة زائدة في الدم.</p><p dir="RTL">- تشنجات فكية, تشنجات عضلية, تقلصات عضلية غير اختيارية, ارتعاش في العضلات.</p><p dir="RTL">- صعوبات في التناسق, التوازن, والمشي.</p><p dir="RTL">- تضيق في الحلق أو الصدر.</p><p dir="RTL">- اضطرابات عينية مثل تدلي الجفن العلوي للعين, رؤية مزدوجة.</p><p dir="RTL">- فقدان أو اعتلال الصوت, غِلظة في الصوت (صوت أجش).</p><p dir="RTL">- إحساس غير طبيعي في اللسان, صعوبة في الكلام.</p><p dir="RTL">- ألم الوجه و/أو ألم العينين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية نادرة ( يمكن أن تؤثر حتى في 1 من كل 1,000 شخص):</strong></p><p dir="RTL">- كلام متلعثم.</p><p dir="RTL">- صمم.</p><p dir="RTL">- أعراض غير مفسرة من جهاز التنفس مثل سعال غير مُنتج, صعوبات أو خشخشات (قرقعات) في التنفس (مرض رئوي فراغي, تليف رئوي).</p><p dir="RTL">- التهاب الأمعاء الغليظة الذي يمكن أن يسبب ألماً في البطن أو إسهالاً (التهاب القولون).</p><p dir="RTL">- حالة دم شاذة (نقص الصفيحات) ناجمة عن رد فعل تحسسي مترافق مع كدمات ونزيف غير طبيعي (قلة الخلايا المناعية الحساسية).</p><p dir="RTL">- نقص خلايا الدم الحمراء بسبب تدهور كبير جداً للدم (فقر الدم الخلالي).</p><p dir="RTL">- انخفاض عابر في حدة الرؤية, اضطراب في مجال الرؤية, التهاب في العصب البصري (التهاب العصب البصري).</p><p dir="RTL">- التهاب المُعثكلة (البنكرياس) الذي يمكن أن يسبب ألماً في أعلى البطن, غثياناً أو اقياءً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>تأثيرات جانبية نادرة جداً (يمكن أن تؤثر حتى في 1 من كل 10,000 شخص):</em></strong></p><p dir="RTL">- مرض في الكبد.</p><p dir="RTL">- التهاب الكليتين وفشل كلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا حدث لك أية تأثيرات جانبية, تحدث إلى طبيبك أو الصيدلي. ويشمل ذلك أية تأثيرات جانبية محتملة غير مدرجة في هذه النشرة. ويمكنك أيضاً أن تبلغ عن التأثيرات الجانبية مباشرة عن طريق المركز الوطني للأدوية والسلامة الدوائية&nbsp;(NBC)&nbsp;+966-11-2038222. التحويلات:&nbsp;2317 - 2356 - 2353 - 2354 - 2334 - 2340. الهاتف المجاني:&nbsp;8002490000. البريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa.</p><p dir="RTL">ويمكنك بالإبلاغ عن التأثيرات الجانبية أن تُساعد في إعطاء المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا يتطلب هذا المستحضر الدوائي أية شروط خاصة للتخزين عندما لا تكون القارورة مفتوحة.</p><p dir="RTL">لا تستخدم&nbsp;<strong>باتيبان</strong>&nbsp;بعد انتهاء صلاحيته المذكورة على العلبة واللصاقة.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تخفيف المحلول المعاد تحضيره على الفور بـ 5% من محلول الغلوكوز لإعطاء تركيز بين 0,2ملغ/مل و 0,7ملغ/مل. حالما يتم التخفيف يجب استخدام محلول التسريب فوراً. وقد ثبتَ كيميائياً وفيزيائياً أن مدة الثبات قيد الاستخدام هي 24 ساعة بدرجة حرارة 2 إلى 8 مئوية.</p><p dir="RTL">يجب أن لا يلامس أوكساليبلاتين العينين أو الجلد. إذا حدث أي إنسكاب عرضي, أخبر الطبيب أو الممرضة فوراً.</p><p dir="RTL">عند انتهاء التسريب, يجب التخلص مما بقي من&nbsp;<strong>باتيبان</strong>&nbsp;بكل عناية من قبل الطبيب أو الممرضة. هذا الدواء معد للاستخدام مرة واحدة فقط؛ ويجب التخلص من أي محلول غير مستخدم وفقاً للمتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي أوكساليبلاتين.</p><p dir="RTL">- المكون الآخر هو لاكتوز مونوهايدرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كل مل واحد من المحلول المركّز المعاد تحضيره على 5ملغ أوكساليبلاتين.</p><p dir="RTL"><strong>قارورة 50ملغ:</strong>&nbsp;كل قارورة تحتوي على 50ملغ أوكساليبلاتين لإعادة التحضير في محلول 10مل.</p><p dir="RTL"><strong>قارورة 100ملغ:</strong>&nbsp;كل قارورة تحتوي على 100ملغ أوكساليبلاتين لإعادة التحضير في محلول 20مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مسحوق للحل لأجل التسريب: مسحوق أبيض أو غالباً أبيض, يتم تقديمه في قارورة زجاجية عديمة اللون لها سدادة مطاطية وغطاء معدني يحتوي على قرص بلاستيك.</p><p dir="RTL">سوف يتم تغليف القارورة بغلاف بلاستيك واقي أو بدون هذا الغلاف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أحجام العبوات:</em></p><p dir="RTL">قارورة واحدة من 50ملغ</p><p dir="RTL">قارورة واحدة من 100ملغ</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">شركة تداوي الطبية الحيوية،</p><p dir="RTL">شارع العليا, الرياض,</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة</strong></p><p dir="RTL">أكتافيس إيطاليا س. ب. أ.</p><p dir="RTL">مصنع نيرفيانو</p><p dir="RTL">شارع باستور 10</p><p dir="RTL">20014 نيرفيانو (إم آي)</p><p dir="RTL">إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batipan 5 mg/ml powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of the reconstituted solution for infusion contains 5mg oxaliplatin.
50 mg vial: Each vial contains 50 mg oxaliplatin for reconstitution in 10 ml of solvent. 100 mg vial: Each vial contains 100 mg oxaliplatin for reconstitution in 20 ml of solvent.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion. A white or almost white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:</p><p>-<br />-&nbsp;4.2</p><p>Adjuvant treatment of stage III (Duke&rsquo;s C) colon cancer after complete resection of primary tumour.<br />Treatment of metastatic colorectal cancer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For adults only.&nbsp;2<br />The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m intravenously repeated every two weeks for 12 cycles (6 months).</p><p>The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m2 intravenously repeated every 2 weeks.</p><p>Dosage given should be adjusted according to tolerability (see section 4.4).</p><p>Oxaliplatin should always be administered before fluoropyrimidines&nbsp;&ndash;&nbsp;i.e. 5 fluorouracil (5 FU).</p><p>Oxaliplatin is administered as a 2- to 6-hour intravenous infusion in 250 to 500 ml of glucose 5% solution (50 mg/ml) to give a concentration between 0.2 mg/ml and 0.70 mg/ml; 0.70 mg/ml is the highest concentration in clinical practice for an oxaliplatin dose of 85 mg/m2.</p><p>Oxaliplatin was mainly used in combination with continuous infusion 5-fluorouracil based regimens. For the two-weekly treatment schedule 5-fluorouracil regimens combining bolus and continuous infusion were used.</p><p>Special Populations</p><p>Renal impairment</p><p>Oxaliplatin has not been studied in patients with severe renal impairment (See section 4.3). In patients with moderate renal impairment, treatment may be initiated at the normally recommended dose (see section 4.4). There is no need for dose adjustment in patients with mild renal dysfunction.</p><p>Hepatic impairment</p><p>In a phase I study including patients with several levels of hepatic impairment, frequency and severity of hepatobiliary disorders appeared to be related to progressive disease and impaired liver function tests at baseline. No specific dose adjustment for patients with abnormal liver function tests was performed during clinical development.</p><p>Elderly patients</p><p>No increase in severe toxicities was observed when oxaliplatin was used as a single agent or in combination with 5-fluorouracil in patients over the age of 65. In consequence no specific dose adaptation is required for elderly patients.</p><p>Method of administration</p><p>Oxaliplatin is administered by intravenous infusion.<br />The administration of oxaliplatin does not require hyperhydration.</p><p>Oxaliplatin diluted in 250 to 500 ml of glucose 5% solution (50 mg/ml) to give a concentration not less than 0.2 mg/ml must be infused either via a peripheral vein or central venous line over 2 to 6 hours. Oxaliplatin infusion must always precede the administration of 5-fluorouracil.</p><p>In the event of extravasation, administration must be discontinued immediately.</p><p>Instructions for use</p><p>Oxaliplatin must be reconstituted and further diluted before use. Only the recommended diluents are to be used to reconstitute and then dilute the freeze-dried medicinal product. (See section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to the excipient listed in section 6.1.
- Breast-feeding. 9
- Myelosuppression prior to start of first course, as evidenced by baseline neutrophils <2x10 /l
and/or platelet count of <100x109/l.
- Peripheral sensitive neuropathy with functional impairment prior to first course. - Severely impaired renal function (creatinine clearance less than 30 ml/min).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oxaliplatin should only be used in specialised departments of oncology and should be administered under the supervision of an experienced oncologist.</p><p>Renal impairment</p><p>Due to limited information on safety in patients with moderately impaired renal function, administration should only be considered after suitable appraisal of the benefit/risk for the patient. In this situation, renal function should be closely monitored and dose adjusted according to toxicity.</p><p>Hypersensitivity reactions</p><p>Special surveillance should be ensured for patients with a history of allergic manifestations to other products containing platinum. In case of anaphylactic manifestations the perfusion should be interrupted immediately and an appropriate symptomatic treatment started. Re-administration of oxaliplatin to such patients is contraindicated.&nbsp;Cross reactions, sometimes fatal, have been reported with all platinum compounds.</p><p>In case of oxaliplatin extravasation, the infusion must be stopped immediately and usual local symptomatic treatment initiated.</p><p>Neurological Symptoms</p><p>Neurological toxicity of oxaliplatin should be carefully monitored, especially if co-administered with other medicinal products with specific neurological toxicity. A neurological examination should be performed before each administration and periodically thereafter.</p><p>For patients who develop acute laryngopharyngeal dysaesthesia (see section 4.8), during or within the hours following the 2-hour infusion, the next oxaliplatin infusion should be administered over 6 hours.</p><p>Peripheral neuropathy</p><p>If neurological symptoms (paraesthesia, dysaesthesia) occur, the following recommended oxaliplatin dosage adjustment should be based on the duration and severity of these symptoms:</p><ul><li><p>- &nbsp;If symptoms last longer than seven days and are troublesome, the subsequent oxaliplatin dose</p><p>should be reduced from 85 to 65 mg/m2&nbsp;(metastatic setting) or 75 mg/m2&nbsp;(adjuvant setting).</p></li><li><p>- &nbsp;If paraesthesia without functional impairment persists until the next cycle, the subsequent oxaliplatin dose should be reduced from 85 to 65 mg/m2&nbsp;(metastatic setting) or 75 mg/m2</p><p>(adjuvant setting).</p></li><li><p>- &nbsp;If paraesthesia with functional impairment persists until the next cycle, oxaliplatin should be</p><p>discontinued.</p></li></ul><p><img alt="page3image16262336" width="78.719998" height="0.360000" src="blob:https://sdi.sfda.gov.sa/4f07d231-44c6-4452-955e-b36fc0d22a82" />&nbsp;<img alt="page3image16255232" width="114.719997" height="0.360000" src="blob:https://sdi.sfda.gov.sa/32f3da13-9afb-4e31-9c22-8f2c4415893f" />&nbsp;<img alt="page3image16262912" width="104.999998" height="0.360000" src="blob:https://sdi.sfda.gov.sa/47427686-4ae0-4e85-aad4-7a4be4f16f1e" />&nbsp;<img alt="page3image16264256" width="100.199998" height="0.360000" src="blob:https://sdi.sfda.gov.sa/515a98fb-7649-4b2e-833a-604b0db23c09" /></p><p>- If these symptoms improve following discontinuation of oxaliplatin therapy, resumption of therapy may be considered.</p><p>Patients should be informed of the possibilities of persistent symptoms of peripheral sensory neuropathy after the end of the treatment. Localised moderate paraesthesias or paraesthesias that may interfere with functional activities can persist after up to 3 years following treatment cessation in the adjuvant setting.</p><p>Nausea, vomiting, diarrhoea and dehydration</p><p>Gastrointestinal toxicity, which manifests as nausea and vomiting, warrants prophylactic and/or therapeutic anti-emetic therapy (see section 4.8.).</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil (5 FU).</p><p>If haematological toxicity occurs (neutrophils &lt; 1.5x109/l or platelets &lt; 50x109/l), administration of the next course of therapy should be postponed until haematological values return to acceptable levels. A full blood count with white cell differential should be performed prior to start of therapy and before each subsequent course.</p><p>Patients must be adequately informed of the risk of diarrhoea/emesis, mucositis/stomatitis and neutropenia after oxaliplatin and 5-fluorouracil administration so that they can urgently contact their treating physician for appropriate management. If mucositis/stomatitis occurs with or without neutropenia, the next treatment should be delayed until recovery from mucositis/stomatitis to grade 1 or less and/or until the neutrophil count is&nbsp;&ge;1.5 x 109/l.</p><p>For oxaliplatin combined with 5-fluorouracil (with or without folinic acid (FA)), the usual dose adjustments for 5-fluorouracil associated toxicities should apply.</p><p>If grade 4 diarrhoea, grade 3-4 neutropenia (neutrophils &lt; 1.0x109/l), grade 3-4 thrombocytopenia (platelets &lt; 50x109/l) occur, the dose of oxaliplatin should be reduced from 85 to 65 mg/m2</p><p>(metastatic setting) or 75 mg/m2&nbsp;(adjuvant setting), in addition to any 5-fluorouracil (5 FU) dose reductions required.</p><p>In the case of unexplained respiratory symptoms such as non-productive cough, dyspnoea, crackles or radiological pulmonary infiltrates, oxaliplatin should be discontinued until further pulmonary investigations exclude an interstitial lung disease or pulmonary fibrosis (see section 4.8).</p><p>Hepatic</p><p><img alt="page4image16288000" width="200.999996" height="0.360000" src="blob:https://sdi.sfda.gov.sa/a34e3582-7ac2-406d-a4d4-cb67bd8ee3e7" />&nbsp;<img alt="page4image16294912" width="34.679999" height="0.360000" src="blob:https://sdi.sfda.gov.sa/e9f837da-7fb7-48d6-9916-599172ab2bca" /></p><p>In cases of abnormal liver function test results or portal hypertension, which does not obviously result from liver metastases, very rare cases of drug induced hepatic vascular disorder should be considered.</p><p>Pregnancy</p><p>For use in pregnant women see section 4.6.</p><p>Fertility</p><p>Genotoxic effects were observed with oxaliplatin in the preclinical studies. Therefore male patients treated with oxaliplatin are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment, because oxaliplatin may have an anti-fertility effect which could be irreversible.</p><p>Women should not become pregnant during treatment with oxaliplatin and should use an effective method of contraception (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients who have received a single dose of 85 mg/m2&nbsp;of oxaliplatin, immediately before administration of 5-fluorouracil (5 FU), no change in the level of exposure to 5-fluorouracil (5 FU) has been observed.</p><p>In vitro, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: erythromycin, salicylates, granisetron, paclitaxel, and sodium valproate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>To date there is no available information on safety of use in pregnant women. In animal studies, reproductive toxicity was observed. Consequently oxaliplatin is not recommended during pregnancy and in women of childbearing potential not using contraceptive measures.</p><p>The use of oxaliplatin should only be considered after suitably appraising the patient of the risk to the foetus and with the patient&#39;s consent.</p><p>Appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women and 6 months for men.</p><p>Breastfeeding</p><p>Excretion in breast milk has not been studied. Breast-feeding is contra-indicated during oxaliplatin therapy.</p><p>Fertility</p><p>Oxaliplatin may have an anti-fertility effect (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, oxaliplatin treatment resulting in an increased risk of dizziness, nausea and vomiting, and other neurologic symptoms that affect gait and balance may lead to a minor or moderate influence on the ability to drive and use machines.</p><p>Vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), may affect patients&#39; ability to drive and use machines. Therefore, patients should be warned of the potential effect of these events on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse events of oxaliplatin in combination with 5-fluorouracil/folinic acid (5-FU/FA) were gastrointestinal (diarrhoea, nausea, vomiting and mucositis), haematological (neutropenia, thrombocytopenia) and neurological (acute and dose cumulative peripheral sensory neuropathy). Overall these adverse events were more frequent and severe with oxaliplatin and 5- FU/FA combination than with 5-FU/FA alone.</p><p>The frequencies reported in the table below are derived from clinical trials in the metastatic and adjuvant settings (having included 416 and 1108 patients respectively in the oxaliplatin + 5- FU/FA treatment arms) and from post marketing experience.</p><p>Frequencies in this table are defined using the following convention: very common (&gt;1/10), common (&gt; 1/100, &lt;1/10), uncommon (&gt; 1/1000, &lt;1/100), rare (&gt; 1/10000, &lt;1/1000), very rare (&lt; 1/10000) not known (cannot be estimated from the available data).</p><p>Further details are given after the table.</p><p>MedDRA Organ Very common Common Uncommon Rare System Class</p><p><img alt="page6image16671168" width="79.559998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ebc4567e-aa25-4686-8269-ba4851c2a07d" />&nbsp;<img alt="page6image16675584" width="86.159998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f8aec3e0-a2ee-4e8a-aa09-30fcf2535312" />&nbsp;<img alt="page6image16664256" width="78.479998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d8820253-f175-4def-868f-4706a1e88e79" />&nbsp;<img alt="page6image16673856" width="64.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/738cc8ff-b759-4122-b727-1155c47b1d75" />&nbsp;<img alt="page6image16675200" width="99.839998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/000ea5f3-cbd6-404a-8f24-02c2de14cdaf" /></p><table><tbody><tr><td><p>Infections and infestations*</p></td><td><p>- Infection</p></td><td><p>- Rhinitis - Upper</p><p>respiratory</p><p>tract infection - Neutropenic</p><p>sepsis</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Blood and lymphatic system disorders*</p></td><td><p>- Anaemia<br />- Neutropenia</p><p>-<br />Thrombocytopen ia</p><p>- Leukopenia<br />- Lymphopenia</p></td><td><p>- Febrile neutropenia</p></td><td>&nbsp;</td><td><p>- Immunoallergic thrombocytopenia</p><p>- Haemolytic anaemia</p></td></tr></tbody></table><p>Immune system&nbsp;- Allergy/allergic&nbsp;disorders*&nbsp;reaction+</p><table><tbody><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>- Anorexia<br />- Hyperglycaemia</p><p>- Hypokalaemia<br />- Hyponatremia<br />- Hypernatraemia</p></td><td><p>- Dehydration</p></td><td><p>- Metabolic acidosis</p></td><td>&nbsp;</td></tr></tbody></table><p><img alt="page7image16352576" width="79.559998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/009fa80b-02e9-449b-892c-2d571c168753" />&nbsp;<img alt="page7image16355264" width="86.159998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/24b7d0da-c68a-4517-9ffe-406e2511c90e" />&nbsp;<img alt="page7image16356224" width="78.479998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7d427781-8acc-4689-a651-e28e4d06c5d4" />&nbsp;<img alt="page7image16365248" width="64.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6b8dbe5b-6624-4402-9dc7-f399309c0bee" />&nbsp;<img alt="page7image16355072" width="99.839998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/575d52da-aaaa-42c4-916b-1686f4c6ad9e" />&nbsp;<img alt="page7image16363712" width="79.559998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/245c084d-ebe5-4026-9c6d-9fdadd6e8e79" />&nbsp;<img alt="page7image16358720" width="86.159998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d5da8a3f-8b3a-4c48-a20c-2065bfc1750d" />&nbsp;<img alt="page7image16365632" width="78.479998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/b99a7e1c-d83c-4c74-9891-6a958f7be8db" />&nbsp;<img alt="page7image16356800" width="64.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0f7ee8af-370e-4c15-90ee-617d3d5f69fb" /><img alt="page7image16351808" width="99.839998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/bf1ab19d-9fe1-4ed5-baf4-e498ab1cb562" /></p><p>Psychiatric disorders</p><p>- Depression - Insomnia</p><p>- Nervousness</p><table><tbody><tr><td><p>Nervous system disorders*</p></td><td><p>- Peripheral sensory neuropathy</p><p>- Sensory disturbance</p><p>- Dysgeusia - Headache</p></td><td><p>- Dizziness<br />- Motor neuritis - Meningism</p></td><td>&nbsp;</td><td><p>- Dysarthria</p></td></tr><tr><td><p>Eye disorders</p></td><td>&nbsp;</td><td><p>- Conjunctivitis - Visual</p><p>disturbance</p></td><td>&nbsp;</td><td><p>- Visual acuity reduced transiently</p><p>- Visual field disturbance</p><p>- Optic neuritis</p></td></tr></tbody></table><p>Ear and labyrinth disorders</p><p>- Ototoxicity</p><p>- Deafness</p><table><tbody><tr><td><p>Vascular disorders</p></td><td>&nbsp;</td><td><p>- Haemorrhage - Flushing</p><p>- Deep vein thrombosis</p><p>- Hypertension</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>- Dyspnoea - Cough<br />- Epistaxis</p></td><td><p>- Hiccups<br />- Pulmonary</p><p>embolism -</p></td><td>&nbsp;</td><td><p>- Interstitial lung disease, sometimes fatal</p><p>- Pulmonary fibrosis**</p></td></tr><tr><td><p>Gastrointestinal disorders*</p></td><td><p>- Nausea<br />- Diarrhoea - Vomiting - Stomatitis/</p><p>mucositis<br />- Abdominal pain - Constipation</p></td><td><p>- Dyspepsia - Gastro-</p><p>esophageal</p><p>reflux - Rectal</p><p>haemorrhage</p></td><td><p>- Ileus<br />- Intestinal</p><p>obstruction</p></td><td><p>- Colitis including Clostridium difficile diarrhoea</p></td></tr></tbody></table><p>Skin and subcutaneous</p><p>- Skin disorder - Alopecia</p><p>- Skin exfolation (i.e</p><p><img alt="page7image16346368" width="79.559998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c9d173a4-166f-4dfe-8345-46092b0290f8" />&nbsp;<img alt="page7image16346944" width="86.159998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d1cb5d22-f2e5-4a4c-90a2-3ce1b0f91109" />&nbsp;<img alt="page7image16346752" width="78.479998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d42bd0d6-5b99-44f3-83b8-a8dc7e4c8ddb" />&nbsp;<img alt="page7image16347136" width="64.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/dd8fdd0f-d76b-480d-b29b-5f69ad13f510" />&nbsp;<img alt="page7image16348672" width="99.839998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/36976a4a-2b8c-4e84-bdc4-43a7704bfacc" /></p><table><tbody><tr><td><p>tissue disorders</p></td><td>&nbsp;</td><td><p>Hand and Foot syndrome)</p><p>- Rash erythematous</p><p>- Rash<br />- Hyperhidrosis - Nail disorder</p></td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Musculoskeletal,&nbsp;- Back pain - Arthralgia&nbsp;connective tissue&nbsp;- Bone pain&nbsp;disorders</p><table><tbody><tr><td><p>Renal and urinary disorders</p></td><td>&nbsp;</td><td><p>- Haematuria - Dysuria<br />- Micturition</p><p>frequency abnormal</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>- Fatigue<br />- Fever++<br />- Asthenia<br />- Pain<br />- Injection site</p><p>reaction+++</p></td><td><p>- Chest pain</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Investigations</p></td><td><p>- Hepatic enzyme increase</p><p>- Blood alkaline phosphatase increase</p><p>- Blood bilirubin increase</p><p>- Blood lactate dehydrogenase increase</p><p>- Weight increase (adjuvant setting)</p></td><td><p>- Blood Creatinine increase</p><p>- Weight decrease (metastatic setting)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&ldquo;See detailed section below</p><p>** See section 4.4.<br />+ Common allergic reactions such as skin rash (particularly urticaria), conjunctivitis, rhinitis. Common anaphylactic reactions, including bronchospasm, sensation of chest pain, angioedema, hypotension and anaphylactic shock.<br />++ Very common fever, rigors (tremors), either from infection (with or without febrile neutropenia) or isolated fever possibly from immunological mechanism.<br />+++ Injection site reactions including local pain, redness, swelling and thrombosis have been reported. Extravasation may also result in local pain and inflammation which may be severe and lead to complications including necrosis, especially when oxaliplatin is infused through a&nbsp;peripheral vein (see 4.4).&rdquo;</p><p>Hepato-biliary disorders</p><p>Very rare (&lt;1/10,000):</p><p>Liver sinusoidal obstruction syndrome, also known as veno-occlusive disease of liver, or pathological manifestations related to such liver disorder, including peliosis hepatis, nodular regenerative hyperplasia, perisinusoidal fibrosis. Clinical manifestations may be portal hypertension and/or increased transaminases.</p><p>Renal and urinary disorders</p><p>Very rare (&lt;1/10,000):<br />Acute tubular necrosis, acute interstitial nephritis and acute renal failure.&nbsp;Blood and lymphatic system disorders:<br />Incidence by patient (%), by grade</p><p><img alt="page9image16325376" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7a7d4100-6bb5-445e-a65d-40fb73938787" />&nbsp;<img alt="page9image16328640" width="130.319997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f2eacf82-3d87-49ef-af4e-7e246fc78504" />&nbsp;<img alt="page9image16328832" width="151.319997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f052b8bb-69d9-447b-b11b-9744da4ce71d" /></p><p>Oxaliplatin and 5-FU/FA 85 mg/m2</p><p>every 2 weeks</p><p>Anemia Neutropenia Thrombocytopenia Febrile neutropenia Neutropenic sepsis</p><p>Metastatic Setting</p><p>All Gr 3 grades</p><p>82.2 3 71.4 28 71.6 4 5.0 3.6 1.1 0.7</p><p>Adjuvant Setting</p><p><img alt="page9image16329024" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ad5749f7-f05a-46ca-9269-6df0d044988d" />&nbsp;<img alt="page9image16329408" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/1c0a753b-4535-45d9-a68e-c3d844d107f6" />&nbsp;<img alt="page9image16329600" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3c7670dd-125b-4c3d-96bd-219ea0482ce0" />&nbsp;<img alt="page9image16330176" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f2b90c0a-94ab-4aa8-b941-7ae4a8b2380c" />&nbsp;<img alt="page9image16329792" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/55d48681-975c-4a1d-b21d-3e099257b761" />&nbsp;<img alt="page9image16330368" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/78d0cc3f-6902-4dd0-9d0e-bf2db9018b5c" />&nbsp;<img alt="page9image16329216" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9a7d5a77-6ef1-4277-a647-6ead831c7fdf" /></p><p>Gr 4</p><p>&lt;1 14 &lt;1 1.4 0.4</p><p>All grades</p><p>75.6 78.9 77.4 0.7 1.1</p><p>Adjuvant</p><p>All grades</p><p>73.7 56.3 47.2 42.1</p><p>Gr3</p><p>0.7 28.8 1.5 0.7 0.6</p><p>Setting</p><p>Gr 3</p><p>4.8 8.3 5.3 2.8</p><p>Gr4</p><p>0.1 12.3 0.2 0.0 0.4</p><p><img alt="page9image16330752" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/714583cd-350c-4291-803b-ad57df2380e4" />&nbsp;<img alt="page9image16329984" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5d2a0cf7-ec7e-4172-93ce-9804ac29429a" />&nbsp;<img alt="page9image16330560" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a636bce9-220e-4c75-8f7b-d8c15927d29d" />&nbsp;<img alt="page9image16330944" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/16b79f8c-6a2f-4573-aca4-10d62074af9c" />&nbsp;<img alt="page9image16331328" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/734eadc5-a4da-4dac-a562-8aab93b9003b" />&nbsp;<img alt="page9image16331520" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7ee1809a-e999-4ec6-81c0-5c43aabb60e7" />&nbsp;<img alt="page9image16331712" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/dec52309-287f-4f48-ac90-8b3dd9c87f9e" />&nbsp;<img alt="page9image16332096" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/adbae2a7-81f6-4046-b78b-5a62cfd633db" />&nbsp;<img alt="page9image16331904" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/179cf653-9d52-4786-b701-10f262357922" />&nbsp;<img alt="page9image16332480" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f07cd40d-24a7-48e5-bbbf-6f955a454bf8" />&nbsp;<img alt="page9image16325760" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/92916c99-abaa-4b93-beab-4d1d3ec8c547" />&nbsp;<img alt="page9image16325568" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a545cbfc-0b21-4ca5-aec6-98bd29d884e6" /><img alt="page9image16333440" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6f4ad2f7-6fbf-4a66-b2a2-041edae5ad1f" />&nbsp;<img alt="page9image16324800" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/458a239d-d069-40a5-a9da-a67427d8e992" />&nbsp;<img alt="page9image16333824" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3042071a-a213-4d1a-8af9-ee9f88f52a0b" />&nbsp;<img alt="page9image16333632" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a55f0cdb-3212-4aa8-8a39-6e28b64ea3bc" />&nbsp;<img alt="page9image16334208" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e4937526-04a3-4407-90cd-32a7f7c7f0c6" />&nbsp;<img alt="page9image16333248" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/fb24e36f-20cb-42ea-9fda-8f0d756031b1" />&nbsp;<img alt="page9image16334016" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/fcf1bac8-d3a2-4a6b-afdc-9c13e1cc64db" />&nbsp;<img alt="page9image16334400" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f6b166e7-d043-4715-8ae2-8a90b287bdd4" />&nbsp;<img alt="page9image16334592" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7d772a10-5b23-4706-95d3-b70120eb2b1c" />&nbsp;<img alt="page9image16332864" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c5226d93-8724-4a35-8ece-78f0acbd815b" />&nbsp;<img alt="page9image16700672" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7229f419-8544-4b54-b5a1-d14b575b9bac" />&nbsp;<img alt="page9image16681600" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5c7dda48-78bd-4f0b-bf17-17cac664c023" /><img alt="page9image16350592" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/629fe84e-889a-44dd-b2f0-7c1d5176ec3e" />&nbsp;<img alt="page9image16350976" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/dc0b0f75-81d0-4aeb-940a-2c53b1c5ae12" />&nbsp;<img alt="page9image16350784" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a8f77793-c3a3-4fb6-bd9b-f696b3eec1e4" />&nbsp;<img alt="page9image16345792" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0714cb1c-bef2-490b-90d7-dfbb49577455" />&nbsp;<img alt="page9image16350400" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/46506309-48f7-4d4a-92ba-ea67937c9b18" />&nbsp;<img alt="page9image16359680" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/aff7dcf6-7ef8-4772-83c5-10b4eca158e5" />&nbsp;<img alt="page9image16359104" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ff80502c-afc6-43e3-8674-da6dc18f1e37" />&nbsp;<img alt="page9image16356032" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/78468d63-7502-4c2d-9038-af998d169311" />&nbsp;<img alt="page9image16361792" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3b69bf79-9465-481c-92aa-ed0a71716e89" />&nbsp;<img alt="page9image16364288" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/99e14ab7-69b0-4096-8517-e1132f9e7fb1" />&nbsp;<img alt="page9image16356416" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/dc1944ab-1670-44ff-8a0d-e81f872474a6" />&nbsp;<img alt="page9image16379328" width="132.839997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2a763261-75f6-4001-af58-d2d8e26b7c05" /><img alt="page9image16382592" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/cc95de3f-6558-4071-9c62-bb6f27085b00" />&nbsp;<img alt="page9image16264640" width="42.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/b2f97ea0-97ec-4efc-b9d8-80c7f07c0611" />&nbsp;<img alt="page9image16256768" width="41.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/60700423-b179-4ca6-a52c-97c9f2488748" />&nbsp;<img alt="page9image16264064" width="56.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/fad76a93-d6e6-431e-bfd7-d248d205857d" />&nbsp;<img alt="page9image16256960" width="46.679999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/54a7066d-b539-4034-a5dd-88b3100bca45" />&nbsp;<img alt="page9image16259072" width="46.439999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/963f3741-d401-4baf-b4b4-83dd9eac0a1c" /></p><p>Postmarketing experience with frequency unknown Hemolytic uremic syndrome</p><p>Gastrointestinal disorders:</p><p>Incidence by patient (%), by grade</p><p><img alt="page9image16257536" width="225.719995" height="0.360000" src="blob:https://sdi.sfda.gov.sa/ae7e3a99-e3b8-46a3-94ef-ad9470bbca5b" />&nbsp;<img alt="page9image16257344" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d37df356-42dd-4e00-9db7-af78b3f03b8f" />&nbsp;<img alt="page9image16257152" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d46348c7-f4b6-425c-bddd-ce62c21b7a74" />&nbsp;<img alt="page9image16268096" width="141.479997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e216b27b-04be-427e-8133-f326835c78fa" /></p><p>Oxaliplatin and 5-FU/FA 85 mg/m2</p><p>Metastatic Setting</p><p><img alt="page9image16265408" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9966c4e8-bb14-420d-969e-f134f29f1c8c" />&nbsp;<img alt="page9image16256000" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/46602a9b-2e36-4229-8655-e5182d97b05b" />&nbsp;<img alt="page9image16263488" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e6e9882e-b404-4582-a446-8e97d932b770" />&nbsp;<img alt="page9image16268288" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f854c36f-298b-42c7-bdf4-39ba66d2b923" />&nbsp;<img alt="page9image16258496" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ba738a06-3893-45b7-a7ab-3ee71c76991c" />&nbsp;<img alt="page9image16263296" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c6715c85-b465-4bdc-9021-3528b5332afa" />&nbsp;<img alt="page9image16301824" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/35e7e8b2-f5a0-485a-b23d-214989a11e25" /></p><p>every 2 weeks&nbsp;All&nbsp;grades</p><p>Nausea&nbsp;69.9&nbsp;Diarrhoea&nbsp;60.8&nbsp;V omiting&nbsp;49.0&nbsp;Mucositis/Stomatitis&nbsp;39.9</p><p>Gr 3</p><p>8 9 6 4</p><p>Gr 4</p><p>&lt;1 2<br />1 &lt;1</p><p>Gr 4</p><p>0.3 2.5 0.5 0.1</p><p><img alt="page9image16286464" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/694c4288-2083-45d7-9f36-2054c3b29028" />&nbsp;<img alt="page9image16289920" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/432544de-b202-4ae5-b454-c0b3d250f7d3" />&nbsp;<img alt="page9image16285888" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/af1d04ad-6a66-4245-af65-9af1a3499136" />&nbsp;<img alt="page9image16294144" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/baad36f6-7644-4377-9ee7-d8b21afb2c66" />&nbsp;<img alt="page9image16285696" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/49fb0585-dcd5-4cef-8d6b-2255ab5c240a" />&nbsp;<img alt="page9image16465920" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ededea19-0cca-4bd2-ba7e-edbbd0342589" />&nbsp;<img alt="page9image16466112" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/00e2487c-430b-413a-9ac1-561c321d8810" />&nbsp;<img alt="page9image16466304" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/001dafba-ac88-447d-bc8c-6a0a76d68f80" />&nbsp;<img alt="page9image16466496" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9f3bd26d-82bb-4343-8286-3640fc05b44d" />&nbsp;<img alt="page9image16466688" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0c323ecf-71ee-4dd9-8c5a-8ba782bfc9c9" />&nbsp;<img alt="page9image16466880" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/633ac496-753b-45af-aaf5-5b46ee901e7c" />&nbsp;<img alt="page9image16467072" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/06eef953-4990-4d33-9595-f90926ebe771" /><img alt="page9image16467264" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/76f460a5-3432-4bda-8b23-03e373cd2b7d" />&nbsp;<img alt="page9image16467456" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d8c42953-af85-4541-9307-757c0bbf93d3" />&nbsp;<img alt="page9image16467648" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/43383863-6a35-4a54-b878-56860cda551b" />&nbsp;<img alt="page9image16467840" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e8382138-63bb-406a-94a4-ca23424f6a15" />&nbsp;<img alt="page9image16468032" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/891d392f-c24b-44e2-bfbe-d3d714bd7589" />&nbsp;<img alt="page9image16468224" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a1cf7ce5-651d-4470-b523-8abc49e8ff65" />&nbsp;<img alt="page9image16468416" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ea486367-5869-4d36-8d5b-91ef0a0e6ec5" />&nbsp;<img alt="page9image16468608" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/401bd87d-ee70-4c2d-a726-63bb3a955203" />&nbsp;<img alt="page9image16468800" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a34e103d-aba5-429d-b8b2-dec8f0e313c9" />&nbsp;<img alt="page9image16468992" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/aebeea6d-4727-41d2-b438-74e2c55a8b5b" />&nbsp;<img alt="page9image16469184" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/eb4fe623-0ca1-46fa-8f63-1de2ed4f668b" />&nbsp;<img alt="page9image16469376" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d4b844a0-184a-4c8d-a85a-a7d6d72baa0a" /><img alt="page9image16469568" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d25753a2-a571-4e61-98c9-12d2b18321ff" />&nbsp;<img alt="page9image16469760" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5c9d9534-845d-4869-ad77-8961c65d530e" />&nbsp;<img alt="page9image16469952" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e39ffb60-03c8-456b-a24f-85c159aa18eb" />&nbsp;<img alt="page9image16470144" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9ec44ab8-08c9-4f1e-8dd1-4c1c83e64f6a" />&nbsp;<img alt="page9image16470336" width="136.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a96b748b-e6e9-49bb-a5d0-e0eaa42dfe67" />&nbsp;<img alt="page9image16470528" width="44.279999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/91059258-433c-4679-993a-ddd69b78c8ed" />&nbsp;<img alt="page9image16470720" width="45.839999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0c3ad755-fa91-421a-8cc8-0dbab3fba049" />&nbsp;<img alt="page9image16470912" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/fcd14255-058c-4d16-9633-60a238f50436" />&nbsp;<img alt="page9image16471104" width="51.359999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c7c3822f-3d21-4385-9014-ad40ebbde3fd" />&nbsp;<img alt="page9image16471296" width="44.399999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9ee9abd5-ceef-4c32-b7a7-66e0cd00c67e" />&nbsp;<img alt="page9image16471488" width="43.799999" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6be3a39c-25e0-4274-8fe7-ba36bcb81464" /></p><p>Prophylaxis and/or treatment with potent antiemetic agents is indicated.</p><p>Dehydration, paralytic ileus, intestinal obstruction, hypokalemia, metabolic acidosis and renal impairment may be caused by severe diarrhoea/emesis particularly when combining oxaliplatin with 5-fluorouracil (5 FU) (see section 4.4).</p><p>Nervous system disorders:</p><p>The dose limiting toxicity of oxaliplatin is neurological. It involves a sensory peripheral neuropathy characterised by dysaesthesia and/or paraesthesia of the extremities with or without cramps, often triggered by the cold. These symptoms occur in up to 95% of patients treated. The</p><p>duration of these symptoms, which usually regress between courses of treatment, increases with the number of treatment cycles.</p><p>The onset of pain and/or a functional disorder are indications, depending on the duration of the symptoms, for dose adjustment, or even treatment discontinuation (see section 4.4).</p><p>This functional disorder includes difficulties in executing delicate movements and is a possible consequence of sensory impairment. The risk of occurrence of persistent symptoms for a cumulative dose of 850 mg/m2 (10 cycles) is approximately 10% and 20% for a cumulative dose of 1020 mg/m2 (12 cycles).</p><p>In the majority of the cases, the neurological signs and symptoms improve or totally recover when treatment is discontinued. In the adjuvant setting of colon cancer, 6 months after treatment cessation, 87 % of patients had no or mild symptoms. After up to 3 years of follow up, about 3 % of patients presented either with persisting localised paraesthesias of moderate intensity (2.3%) or with paraesthesias that may interfere with functional activities (0.5%).</p><p>Acute neurosensory manifestations (see section 5.3) have been reported. They start within hours of administration and often occur on exposure to cold. They usually present as transient paraesthesia, dysaesthesia and hypoesthesia. An acute syndrome of pharyngolaryngeal dysaesthesiaoccurs in 1% - 2% of patients and is characterised by subjective sensations of dysphagia or dyspnoea/feeling of suffocation, without any objective evidence of respiratory distress (no cyanosis or hypoxia) or of laryngospasm or bronchospasm (no stridor or wheezing). Although antihistamines and bronchodilators have been administered in such cases, the symptoms are rapidly reversible even in the absence of treatment. Prolongation of the infusion helps to reduce the incidence of this syndrome (see section 4.4). Occasionally other symptoms that have been observed include jaw spasm/muscle spasms/muscle contractions-involuntary/muscle twitching/myoclonus, coordination abnormal/gait abnormal/ ataxia/ balance disorders, throat or chest tightness/ pressure/ discomfort/pain. In addition, cranial nerve dysfunctions may be associated, or also occur as an isolated event such as ptosis, diplopia, aphonia/ dysphonia/ hoarseness, sometimes described as vocal cord paralysis, abnormal tongue sensation or dysarthria, sometimes described as aphasia, trigeminal neuralgia/ facial pain/ eye pain, decrease in visual acuity, visual field disorders.</p><p>Other neurological symptoms such as dysarthria, loss of deep tendon reflex and Lhermitte&#39;s sign were reported during treatment with oxaliplatin. Isolated cases of optic neuritis have been reported.</p><p>Immune system disorders:</p><p>Incidence by patient (%), by grade</p><p><img alt="page10image16316480" width="126.119997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2b6617a7-9df3-4a18-9dc9-3d1b9d4539bc" />&nbsp;<img alt="page10image16318016" width="142.919997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/37aa61f2-9d6e-490b-b436-016d2c7895de" />&nbsp;<img alt="page10image16314944" width="145.439997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/8d1ba178-534f-417a-bd57-b19dcdee8bec" /></p><p>Oxaliplatin and 5-FU/FA 85 mg/m2</p><p>every2weeks</p><p>Allergic reactions / Allergy</p><p>4.9 Overdose</p><p>Metastatic Setting</p><p>Allgrades Gr3</p><p>9.1 1</p><p>Gr4</p><p>&lt; 1</p><p>Adjuvant Setting</p><p>Allgrades Gr3 Gr4</p><p>10.3 2.3 0.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote to oxaliplatin. In cases of overdose, exacerbation of adverse events can be expected. Monitoring of haematological parameters should be initiated and symptomatic treatment given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties</p><p>Pharmacotherapeutic group: Other antineoplastic agents, platinum compounds. ATC code : L01XA 03</p><p>Oxaliplatin is an antineoplastic drug belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (&ldquo;DACH&rdquo;)&nbsp;and an oxalate group.</p><p>Oxaliplatin is a single enantiomer, the Cis-[oxalato(trans-l-1,2- DACH) platinum].</p><p>Oxaliplatin exhibits a wide spectrum of both&nbsp;in vitro&nbsp;cytotoxicity and&nbsp;in vivo&nbsp;antitumour activity in a variety of tumour model systems including human colorectal cancer models. Oxaliplatin also demonstrates&nbsp;in vitro&nbsp;and&nbsp;in vivo&nbsp;activity in various cisplatin resistant models.</p><p>A synergistic cytotoxic action has been observed in combination with 5-fluorouracil both&nbsp;in vitro&nbsp;and&nbsp;in vivo.</p><p>Studies on the mechanism of action of oxaliplatin, although not completely elucidated, show that the aqua-derivatives resulting from the biotransformation of oxaliplatin, interact with DNA to form both inter and intra-strand cross-links, resulting in the disruption of DNA synthesis leading to cytotoxic and antitumour effects.</p><p>In patients with metastatic colorectal cancer, the efficacy of oxaliplatin (85mg/m2&nbsp;repeated every two weeks) combined with 5-fluorouracil/folinic acid (5-FU/FA) is reported in three clinical studies:</p><ul><li><p>- &nbsp;In front-line treatment, the 2-arm comparative phase III EFC2962 study randomised 420 patients either to 5-FU/FA alone (LV5FU2, N=210) or the combination of oxaliplatin with 5- FU/FA (FOLFOX4, N=210)</p></li><li><p>- &nbsp;In pretreated patients, the comparative three arms phase III study EFC4584 randomised 821 patients refractory to an irinotecan (CPT-11) + 5-FU/FA combination either to 5-FU/FA alone (LV5FU2, N=275), oxaliplatin single agent (N=275), or combination of oxaliplatin with 5- FU/FA (FOLFOX4, N=271).</p></li><li><p>- &nbsp;Finally, the uncontrolled phase II EFC2964 study included patients refractory to 5-FU/FA alone, that were treated with the oxaliplatin and 5-FU/FA combination (FOLFOX4, N=57)</p><p>The two randomised clinical trials, EFC2962 in front-line therapy and EFC4584 in pretreated patients, demonstrated a significantly higher response rate and a prolonged progression free survival (PFS)/time to progression (TTP) as compared to treatment with 5-FU/FA alone. In EFC4584 performed in refractory pretreated patients, the difference in median overall survival (OS) between the combination of oxaliplatin and 5-FU/FA did not reach statistical significance.</p><p>Response rate under FOLFOX4 versus LV5FU2</p></li></ul><p>Front-line treatment&nbsp;22 49 NA* EFC2962 (16-27) (42-46)</p><table><tbody><tr><td><p>Response rate, %<br />(95% CI)<br />independent radiological review ITT analysis</p></td><td><p>LV5FU2</p></td><td><p>FOLFOX4</p></td><td><p>Oxaliplatin Single agent</p></td></tr></tbody></table><p><img alt="page11image16070912" width="178.679996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6f7987da-a439-4677-999d-06752a2acc12" />&nbsp;<img alt="page11image16071488" width="78.719998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/1cc4482e-9279-44f4-964b-acd3fb11b2a6" />&nbsp;<img alt="page11image16071680" width="74.519998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2186b324-8050-4c04-a139-588bf6fb0d65" />&nbsp;<img alt="page11image16071296" width="81.599998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d8efcf9c-e6af-409b-bef5-33c97318b823" /></p><p><img alt="page12image15949120" width="178.679996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/579e26bf-5824-48de-b99f-cace2b90f0cc" />&nbsp;<img alt="page12image15948928" width="154.199997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/10514733-f6c4-4ce8-a1b8-5019ddda4596" />&nbsp;<img alt="page12image15948736" width="81.599998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/12240581-1915-40cc-8fbb-a10f11323763" /></p><p>Response assessment every 8 weeks P value = 0.0001</p><p>Response assessment every 6 weeks P value&nbsp;&lt;&nbsp;0.0001</p><p>NA: Not Applicable<br />Median Progression Free Survival (PFS) / Median Time to Progression (TTP)</p><table><tbody><tr><td><p>Pretreated patients</p><p>EFC4584<br />(refractory to CPT-11 + 5-FU/FA)</p></td><td><p>0.7 (0.0-2.7)</p></td><td><p>11.1 (7.6-15.5)</p></td><td><p>1.1 (0.2-3.2)</p></td></tr></tbody></table><table><tbody><tr><td><p>Pretreated patients</p><p>EFC2964<br />(refractory to 5-FU/FA)<br />Response assessment every 12 weeks</p></td><td><p>NA*</p></td><td><p>23 (13-36)</p></td><td><p>NA*</p></td></tr></tbody></table><p>FOLFOX4 versus LV5FU2</p><p>Front-line treatment</p><p>EFC2962 (PFS)</p><p>Pretreated patients</p><p>EFC4584 (TTP)<br />(refractory to CPT-11 + 5-FU/FA)</p><p>6.0 8.2 NA* (5.5-6.5) (7.2-8.8)</p><p>Log-rank P value = 0.0003</p><p>2.6 5.3 2.1 (1.8-2.9) (4.7-6.1) (1.6-2.7)</p><p>Log-rank P value&nbsp;&lt;&nbsp;0.0001</p><table><tbody><tr><td><p>Median PFS/TTP, Months (95% CI) independent radiological review ITT analysis</p></td><td><p>LV5FU2</p></td><td><p>FOLFOX4</p></td><td><p>Oxaliplatin Single agent</p></td></tr></tbody></table><p><img alt="page12image15764096" width="175.079996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e2a30c38-f3c6-45d3-85d9-73d12e34e72b" />&nbsp;<img alt="page12image15764288" width="78.239998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/94369f6a-f2a0-4cda-8bc0-cb2dac05dc98" />&nbsp;<img alt="page12image15764864" width="80.759998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9bd1971a-6c41-49db-aa12-458e3ab88980" />&nbsp;<img alt="page12image15766016" width="79.439998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/312c9f79-b4b2-4df2-93b1-f07c9f362ee6" />&nbsp;<img alt="page12image15768704" width="175.079996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/68b8aa5c-6332-41e5-88ef-fc7c6f91d9b1" />&nbsp;<img alt="page12image15768320" width="78.239998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d218def5-8650-47f7-aa1e-82be755811a8" />&nbsp;<img alt="page12image15773120" width="80.759998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/bfc92528-0f04-45ab-ae32-98075194669e" /><img alt="page12image15769472" width="79.439998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/810ec705-426e-4b07-82a7-783a477b908e" />&nbsp;<img alt="page12image15777344" width="175.079996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5ba6085c-b6e6-42ac-90b9-d787d1129bae" />&nbsp;<img alt="page12image15766208" width="78.239998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f448cb1a-740f-48b0-a922-50526031ad38" />&nbsp;<img alt="page12image15774080" width="80.759998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/c58261c0-cca5-4653-b34c-8173b073885d" />&nbsp;<img alt="page12image15768896" width="79.439998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3aa35d80-3385-4465-8fb2-fbfa87615844" />&nbsp;<img alt="page12image15767936" width="175.079996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/1cc9c63f-6c17-4fd7-9721-aba1fab0aeab" />&nbsp;<img alt="page12image15773888" width="78.239998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/42336341-59f6-4972-b7d2-931f5ad33519" /><img alt="page12image15777536" width="80.759998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/8c202712-1e79-4bd6-926f-3bce0f6b6fdc" />&nbsp;<img alt="page12image15777152" width="79.439998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/6327f790-0312-4523-9109-163ecc64ae60" /></p><table><tbody><tr><td><p>Pretreated patients</p><p>EFC2964<br />(refractory to 5-FU/FA)</p></td><td><p>NA*</p></td><td><p>5.1 (3.1-5.7)</p></td><td><p>NA*</p></td></tr></tbody></table><p>NA: Not Applicable<br />Median Overall Survival (OS) under FOLFOX4 versus LV5FU2</p><p>Front-line treatment&nbsp;14.7 16.2 NA* EFC2962 (13.0-18.2) (14.7-18.2)</p><p>Log-rank P value = 0.12</p><table><tbody><tr><td><p>Median OS, months (95% CI)<br />ITT analysis</p></td><td><p>LV5FU2</p></td><td><p>FOLFOX4</p></td><td><p>Oxaliplatin Single agent</p></td></tr></tbody></table><p><img alt="page12image15770816" width="172.199996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/43f94d96-d379-4658-a95b-9f9e8b7b4a4c" />&nbsp;<img alt="page12image15770432" width="76.919998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/bd840891-a82b-4a14-9d5e-32ceb7d94beb" />&nbsp;<img alt="page12image15770624" width="76.199998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/bff11091-8bb2-4ec3-bc2d-1d92053bc306" />&nbsp;<img alt="page12image15770048" width="88.199998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a212cfed-2f45-4b1b-b90b-c3b3aa7e4742" /></p><table><tbody><tr><td><p>Pretreated patients</p><p>EFC4584<br />(refractory to CPT-11 + 5-FU/FA)</p></td><td><p>8.8<br />(7.3 - 9.3)</p></td><td><p>9.9 (9.1-10.5)</p></td><td><p>8.1 (7.2-8.7)</p></td></tr></tbody></table><p>Log-rank P value = 0.09</p><p><img alt="page12image15766784" width="172.199996" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e2bb8862-31a5-400d-9d84-124cd8f3c95f" />&nbsp;<img alt="page12image15766400" width="154.079997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/47f252f8-68ec-4f69-99fe-9b57dbff19e8" />&nbsp;<img alt="page12image15765824" width="88.199998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/edfb2014-5c6f-46c9-bd85-fb13f2a553db" /></p><table><tbody><tr><td><p>Pretreated patients</p><p>EFC2964<br />(refractory to 5-FU/FA)</p></td><td><p>NA*</p></td><td><p>10.8 (9.3-12.8)</p></td><td><p>NA*</p></td></tr></tbody></table><p>*NA: Not Applicable</p><p>In pretreated patients (EFC4584), who were symptomatic at baseline, a higher proportion of those treated with oxaliplatin and 5-FU/FA experienced a significant improvement of their disease- related symptoms compared to those treated with 5-FU/FA alone (27.7% vs 14.6% p = 0.0033).</p><p>In non-pretreated patients (EFC2962), no statistically significant difference between the two treatment groups was found for any of the quality of life dimensions. However, the quality of life scores were generally better in the control arm for measurement of global health status and pain and worse in the oxaliplatin arm for nausea and vomiting.</p><p>In the adjuvant setting, the MOSAÏC comparative phase III study (EFC3313) randomised 2246 patients (899 stage II/Duke&#39;s B2 and 1347 stage III/Duke&#39;s C) further to complete resection of the primary tumour of colon cancer either to 5-FU/FA alone (LV5FU2, N=1123 (B2/C = 448/675) or to combination of oxaliplatin and 5-FU/FA (FOLFOX4, N=1123 (B2/C) = 451/672).</p><p>EFC 3313 3-year disease free survival (ITT analysis)* for the overall population.</p><p><img alt="page13image15730368" width="211.799995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a91e35e4-3083-4ed5-8cd8-4e3ca11576b9" />&nbsp;<img alt="page13image15730560" width="113.639997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2303297d-0e4f-47d2-934e-b966d2beb6c5" />&nbsp;<img alt="page13image15730752" width="89.039998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ca164898-5a5c-4553-89b1-706fb0876c44" /></p><p>Treatment arm</p><p>Percent 3-year disease free survival (95% CI)</p><p>Hazard ratio (95% CI)</p><p>P=0.0008<br />* median follow up 44.2 months (all patients followed for at least 3 years)</p><p>LV5FU2</p><p>73.3 (70.6-75.9)</p><p>0.76 (0.64-0.89)</p><p>FOLFOX4</p><p>78.7 (76.2-81.1)</p><p><img alt="page13image15730944" width="211.799995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/5cfb0436-ede8-4f2e-8912-c7c6f2a49684" />&nbsp;<img alt="page13image15731136" width="113.639997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/ccdd2415-f152-4a41-a04e-2e7cb71eb793" />&nbsp;<img alt="page13image15731328" width="89.039998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/0fc43cd9-7076-46de-9968-83fbbdd78cc3" />&nbsp;<img alt="page13image15731520" width="211.799995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/00ef6446-ead5-41b1-a4f7-b3ed601a90ca" />&nbsp;<img alt="page13image15731712" width="113.639997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a8efef15-9336-477a-b3a4-0c8cc32d347b" /><img alt="page13image15731904" width="89.039998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/78c10470-bf0f-4900-ad7a-f1120de8451e" />&nbsp;<img alt="page13image15732096" width="211.799995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/9e57d91e-423a-4bb6-bf17-b2d4e0dd57e5" />&nbsp;<img alt="page13image15732288" width="203.639995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/411fdd3d-3826-4943-a233-bd8efeb71ed3" /></p><p>Stratified log rank test</p><p><img alt="page13image15732480" width="211.799995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3879d4ce-bfce-4cc1-92c5-2021e1289d3c" />&nbsp;<img alt="page13image15732672" width="203.639995" height="0.720000" src="blob:https://sdi.sfda.gov.sa/f332c8d9-8c01-4ad4-b9d6-1f528803efa3" /></p><p>The study demonstrated an overall significant advantage in 3-year disease free survival for the oxaliplatin and 5-FU/FA combination (FOLFOX4) over 5-FU/FA alone (LV5FU2).</p><p>EFC 3313 3-year Disease Free Survival (ITT analysis)* according to Stage of disease</p><p><img alt="page13image15732864" width="130.799997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a464c390-cf5e-4475-a52b-12f735c80652" />&nbsp;<img alt="page13image15733056" width="145.679997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/2a0cb810-2d96-4a1b-9902-d233a76b54c9" />&nbsp;<img alt="page13image15733248" width="137.879997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d01a8028-b226-40f6-b43c-9ff66ef30caa" /></p><p>Patient stage</p><p>Treatment arm</p><p>Hazard ratio (95% CI)</p><p>Stage II (Duke&#39;s B2)</p><p>LV5FU2</p><p>0.79 (0.57-1.09)</p><p>FOLFOX4</p><p>Stage III (Duke&#39;s C)</p><p>LV5FU2</p><p>0.75 (0.62-0.90)</p><p>FOLFOX4</p><p><img alt="page13image15733440" width="130.799997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/e22240d2-2036-453d-b7f1-293f885cf881" />&nbsp;<img alt="page13image15733632" width="76.079998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/a3c8c220-70b1-41d9-b0d2-d952610165eb" />&nbsp;<img alt="page13image15733824" width="68.639998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/7a782a7e-fd9f-4087-b69c-d9a641726a44" />&nbsp;<img alt="page13image15734016" width="68.639998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/cae376cf-c1c3-4e17-b769-b42d76a2395a" />&nbsp;<img alt="page13image15734208" width="68.279998" height="0.720000" src="blob:https://sdi.sfda.gov.sa/d9722545-4436-489f-a305-33bfb0126d31" /></p><table><tbody><tr><td><p>Percent 3-year disease free survival<br />(95% CI)</p></td><td><p>84.3 (80.9-87.7)</p></td><td><p>87.4 (84.3-90.5)</p></td><td><p>65.8 (62.2-69.5)</p></td><td><p>72.8 (69.4-76.2)</p></td></tr></tbody></table><p><img alt="page13image15737472" width="130.799997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/21b1e30a-0adf-4772-b3f9-18e1f48d7c3d" />&nbsp;<img alt="page13image15737664" width="145.679997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/3935898e-7873-4562-a960-aabe8e8d5379" />&nbsp;<img alt="page13image15737856" width="137.879997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/1ca3cfe3-525e-4218-b947-44832668b2f3" /></p><p>P=0.151<br />median follow up 44.2 months (all patients followed for at least 3 years)</p><p>Overall Survival (ITT analysis):</p><p>Log-rank test</p><p>P=0.002</p><p><img alt="page13image15738048" width="130.799997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/cd65a822-4a54-44d8-91ff-835a47a1afa9" />&nbsp;<img alt="page13image15738240" width="145.679997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/1977f5a6-d9db-4166-a02b-94a095d6b837" />&nbsp;<img alt="page13image15738432" width="137.879997" height="0.720000" src="blob:https://sdi.sfda.gov.sa/47d196f9-4893-4b34-9e5b-8c90df66c691" /></p><p>At time of the analysis of the 3-year disease free survival, which was the primary endpoint of the MOSAIC trial, 85.1% of the patients were still alive in the FOLFOX4 arm versus 83.8% in the</p><p>LV5FU2 arm. This translated into an overall reduction in mortality risk of 10% in favour of FOLFOX4 not reaching statistical significance (hazard ratio = 0.90).</p><p>The figures were 92.2% versus 92.4% in the stage II (Duke&#39;s B2) sub-population (hazard ratio = 1.01) and 80.4% versus 78.1% in the stage III (Duke&#39;s C) sub-population (hazard ratio = 0.87), for FOLFOX4 and LV5FU2, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of renal impairment on the disposition of oxaliplatin was studied in patients with varying degrees of renal function. Oxaliplatin was administered at a dose of 85 mg/m2 in the control group with a normal renal function (CLcr &gt; 80 ml/min, n=12) and in patients with mild (CLcr = 50 to 80 ml/min, n=13) and moderate (CLcr = 30 to 49 ml/min, n=11) renal impairment, and at a dose of 65mg/m2 in patients with severe renal impairment (CLcr &lt; 30 ml/min, n=5). Median exposure was 9, 4, 6, and 3 cycles, respectively, and PK data at cycle 1 were obtained in 11, 13, 10, and 4 patients respectively.</p><p>There was an increase in plasma ultrafiltrate (PUF) platinum AUC, AUC/dose and a decrease in total and renal CL and Vss with increasing renal impairment especially in the (small) group of patients with severe renal impairment: point estimate (90% CI) of estimated mean ratios by renal status versus normal renal function for AUC/dose were 1.36 (1.08, 1.71), 2.34 (1.82, 3.01) and 4.81 (3.49, 6.64) for patients with mild and moderate and in severe renal failure respectively. Elimination of oxaliplatin is significantly correlated with the creatinine clearance. Total PUF platinum CL was respectively 0.74 (0.59, 0.92), 0.43 (0.33, 0.55) and 0.21 (0.15, 0.29) and for Vss respectively 0.52 (0.41, 0.65), 0.73 (0.59, 0.91) and 0.27 (0.20, 0.36) for patients with mild, moderate and severe renal failure respectively. Total body clearance of PUF platinum was therefore reduced by respectively 26% in mild, 57% in moderate, and 79% in severe renal impairment compared to patients with normal function.</p><p>Renal clearance of PUF platinum was reduced in patients with impaired renal function by 30% in mild, 65% in moderate, and 84% in severe renal impairment compared to patients with normal function.<br />There was an increase in beta half life of PUF platinum with increasing degree of renal impairment mainly in the severe group. Despite the small number of patients with severe renal dysfunction, these data are of concern in patients in severe renal failure and should be taken into account when prescribing oxaliplatin in patients with renal impairment (see sections 4.2, 4.3 and 4.4).</p><p>A significant decrease in clearance from 17.6 &plusmn; 2.18 l/h to 9.95 &plusmn; 1.91 l/h in renal impairment was observed together with a statistically significant decrease in distribution volume from 330 &plusmn; 40.9 to 241 &plusmn; 36.1 l. The effect of severe renal impairment on platinum clearance has not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The target organs identified in preclinical species (mice, rats, dogs, and/or monkeys) in single- and multiple-dose studies included the bone marrow, the gastrointestinal system, the kidney, the testes, the nervous system, and the heart. The target organ toxicities observed in animals are consistent with those produced by other platinum-containing drugs and DNA-damaging,<br />cytotoxic drugs used in the treatment of human cancers with the exception of the effects produced on the heart. Effects on the heart were observed only in the dog and included electrophysiological disturbances with lethal ventricular fibrillation. Cardiotoxicity is considered specific to the dog not only because it was observed in the dog alone but also because doses similar to those producing lethal cardiotoxicity in dogs (150 mg/m2) were well-tolerated by humans. Preclinical studies using rat sensory neurons suggest that the acute neurosensory symptoms related to Oxaliplatin may involve an interaction with voltage-gated Na+ channels.</p><p>Oxaliplatin was mutagenic and clastogenic in mammalian test systems and produced embryo- fetal toxicity in rats. Oxaliplatin is considered a probable carcinogen, although carcinogenic studies have not been conducted.</p><p>National Pharmacovigilance and Drug Safety Center (NPC) Saudi Food and Drug Authority-Drug sector<br />3292 Northern Ring Road<br />Al Nafal District</p><p>Riyadh 13312&nbsp;&ndash;&nbsp;6288</p><p>Kingdom of Saudi Arabia</p><p>Toll free number: 8002490000</p><p>Call center: 19999</p><p>Tel: 01 2038222 ext. 2317, 2356, 2340</p><p>Fax: 01 2057662<br />Email: NPC.Drug@sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be mixed with other medicinal products except for those mentioned in section 6.6. Oxaliplatin can be co-administered with folinic acid (FA) via a Y-line.</p><p>Do not mix with alkaline medicinal products or solutions, in particular 5-fluorouracil, folinic acid preparations containing trometamol as an excipient and trometamol salts of other active substances. Alkaline medicinal products or solutions will adversely affect the stability of oxaliplatin (see section 6.6).</p><p>Do not reconstitute or dilute for infusion with saline or other solutions containing chloride ions (including calcium, potassium or sodium chloride).</p><p>Do not mix with other medicinal products in the same infusion bag or infusion line (see section 6.6)</p><p>Do not use injection equipment containing aluminium.</p><p>6.3 Shelf life</p><p>Medicinal product as packaged for sale:</p><p>4 years&nbsp;.&nbsp;Reconstituted solution in the original vial:</p><p>The reconstituted solution should be diluted immediately.</p><p>Infusion preparation:</p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C. From a microbiological point of view, the infusion preparation should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C, unless dilution has taken place in controlled and validated aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Medicinal product as packaged for sale:
4 years                    . Reconstituted solution in the original vial:
The reconstituted solution should be diluted immediately.
Infusion preparation:
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C. From a microbiological point of view, the infusion preparation should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicinal product as packaged for sale:</p><p>This medicinal product does not require any special storage conditions.<br />For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass vial (type I) with bromobutyl rubber closures and metallic cap (aluminium) with polypropylene disk.<br />Vial will be packed with or without a protective plastic overwrap.</p><p>Pack sizes:</p><p>1 x 50 mg vial 1 x 100 mg vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other potentially toxic compounds, caution should be exercised when handling and preparing oxaliplatin solutions.</p><p>Instructions for Handling</p><p>The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee the protection of the handler and his surroundings.</p><p>The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicines, in accordance with the hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area.</p><p>Personnel must be provided with appropriate handling materials, notably long sleeved gowns, protection masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste.</p><p>Excreta and vomit must be handled with care.</p><p>Pregnant women must be warned to avoid handling cytotoxic agents.</p><p>Any broken container must be treated with the same precautions and considered as contaminated waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below chapter&nbsp;&ldquo;Disposal&rdquo;.</p><p>If Oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with skin, wash immediately and thoroughly with water.</p><p>If Oxaliplatin powder, reconstituted solution or solution for infusion, should come into contact with mucous membranes, wash immediately and thoroughly with water.</p><p>Special precautions for administration</p><p>- DO NOT use injection equipment containing aluminium.</p><p>- DO NOT administer undiluted.</p><p>- Only glucose 5 % (50 mg/ml) infusion solution is to be used as a diluent. DO NOT reconstitute or dilute for infusion with sodium chloride or chloride containing solutions.</p><p>- DO NOT mix with any other medicinal products in the same infusion bag or administer simultaneously by the same infusion line.</p><p>- DO NOT mix with alkaline medicinal products or solutions, in particular 5 fluorouracil, folinic acid preparations containing trometamol as an excipient and trometamol salts of others active substances. Alkaline medicinal products or solutions will adversely affect the stability of oxaliplatin.</p><p>Instruction for use with folinic acid (FA) (as calcium folinate or disodium folinate)</p><p>Oxaliplatin 85 mg/m2 intravenous infusion in 250 to 500 ml of glucose 5 % (50 mg/ml) solution is given at the same time as folinic acid (FA) intravenous infusion in glucose 5 % solution, over 2 to 6 hours, using a Y-line placed immediately before the site of infusion.</p><p>These two medicinal products should&nbsp;not&nbsp;be combined in the same infusion bag. Folinic acid (FA) must not contain trometamol as an excipient and must only be diluted using isotonic glucose 5 % solution, never in alkaline solutions or sodium chloride or chloride containing solutions.</p><p>Instruction for use with 5 fluorouracil (5 FU)</p><p>Oxaliplatin should always be administered before fluoropyrimidines&nbsp;&ndash;&nbsp;i.e. 5 fluorouracil (5 FU).</p><p>After oxaliplatin administration, flush the line and then administer 5 fluorouracil (5 FU).</p><p>For additional information on medicinal products combined with oxaliplatin, see the corresponding manufacturer&#39;s summary of product characteristics.</p><p>Any reconstituted solution that shows evidence of precipitation should not be used and should be destroyed with due regard to legal requirements for disposal of hazardous waste.</p><p>Reconstitution of the solution</p><p>Water for injections or 5% glucose solution should be used to reconstitute the solution:</p><p>- For a vial of 50 mg: add 10 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml. - For a vial of 100 mg: add 20 ml of solvent to obtain a concentration of 5 mg oxaliplatin/ml.</p><p>Only to be used with recommended diluents.<br />Reconstituted solutions should be diluted immediately with 5% glucose solution. Inspect visually prior to use. Only clear solutions without particles should be used.</p><p>The medicinal product is for single use only. Any unused infusion solution should be discarded.</p><p>Dilution for intravenous infusion</p><p>Withdraw the required amount of reconstituted solution from the vial(s) and then dilute with 250 ml to 500 ml of a 5% glucose solution to give an oxaliplatin concentration between not less than</p><p>0.2 mg/ml and 0.7 mg/ml. The concentration range over which the physico-chemical stability of oxaliplatin has been demonstrated is 0.2 mg/ml to 0.7 mg/ml.</p><p>Administer by intravenous infusion.</p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at 2&deg;C to 8&deg;C. From a microbiological point of view, this infusion preparation should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.</p><p>Inspect visually prior to use. Only clear solutions without particles should be used.<br />The medicinal product is for single use only. Any unused infusion solution should be discarded.</p><p>NEVER use sodium chloride solution or chloride containing solutions for either reconstitution or dilution.</p><p>The compatibility of Oxaliplatin solution for infusion has been tested with representative, PVC- based, administrative sets.</p><p>Infusion</p><p>The administration of oxaliplatin does not require prehydration.<br />Oxaliplatin reconstituted and diluted in 250 to 500 ml of a 5% glucose solution to give a concentration not less than 0.2 mg/ml must be infused either by peripheral vein or central venous line over 2 to 6 hours. When oxaliplatin is administered with 5-fluorouracil, the oxaliplatin infusion must precede the administration of 5-fluorouracil.</p><p>Disposal</p><p>Remnants of the medicinal product as well as all materials that have been used for reconstitution, for dilution and administration must be destroyed according to standard procedures applicable to cytotoxic agents in accordance with local requirements related to the disposal of hazardous waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadaw   iomedical company Olaya st, Riyadh,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>